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Clustered regularly interspaced short palindromic repeat (CRISPR) 
loci and their associated (Cas) proteins provide adaptive immunity against 
viral attack in prokaryotes. Upon infection, short phage sequences known as 
spacers integrate between CRISPR repeats and are transcribed into small 
RNA molecules that guide the Cas9 nuclease to the viral targets 
(protospacers). Streptococcus pyogenes Cas9 cleavage of the viral genome 
requires the presence of a 5′-NGG-3′ protospacer adjacent motif (PAM) 
sequence immediately downstream of the viral target. Before my graduate 
work, it was not known whether and how viral sequences flanked by the 
correct PAM are chosen as new spacers. My work revealed that Cas9 
selects functional spacers by recognizing their PAM during spacer 
acquisition. The replacement of cas9 with alleles that lack the PAM 
recognition motif or recognize an NGGNG PAM eliminates or changes PAM 
specificity during spacer acquisition, respectively. Cas9 associates with 
other proteins of the acquisition machinery (Cas1, Cas2 and Csn2), 
presumably to provide PAM-specificity to this process. This was a newly 
identified function of Cas9 in the genesis of prokaryotic immunological 
memory.  
 
To further explore the link between Cas9 and spacer acquisition, I 
performed random mutagenesis of the RNA-guided Cas9 nuclease to look for 
variants that provide enhanced immunity against viral infection. I identified a 
mutation, I473F, which increases the rate of spacer acquisition by more than 
two orders of magnitude. This patented variant of Cas9 highlights the enzyme’s 
role during CRISPR immunization, provides a useful tool to study this 
otherwise rare process, and holds promise to be developed into a 
biotechnological application.  
 
Researching Cas9 and spacer acquisition involved many rounds of 
high-throughput sequencing of millions of spacers acquired by bacteria during 
phage infection. These experiments revealed that the abundance of each 
spacer in the surviving population was highly uneven. Since the molecular 
mechanisms underlying this bias were not known, I decided to look into the 
factors that affect the distribution of individual spacer sequences during phage 
infection of cells harboring the CRISPR system from Streptococcus pyogenes. 
My work has shown that spacer patterns are established early during infection 
and correlate with spacer acquisition rates, but not with spacer targeting 
efficiency. The data suggests that the rate of spacer acquisition depends on 
unique sequence elements within the spacers and therefore determines the 
abundance of different spacers within the adapted population. These results 
elucidate a fundamental mechanism behind the generation of immunological 
diversity during the type II CRISPR-Cas response. 
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Clustered, regularly interspaced, short palindromic repeats (CRISPR) loci 
and their associated genes (cas) confer bacteria and archaea with adaptive 
immunity against phages and other invading genetic elements. A fundamental 
requirement of any immune system is the ability to build a memory of past 
infections in order to deal more efficiently with recurrent infections. The adaptive 
feature of CRISPR-Cas immune systems relies on their ability to memorize DNA 
sequences of invading molecules and integrate them in between the repetitive 
sequences of the CRISPR array in the form of ‘spacers’. The transcription of a 
spacer generates a small antisense RNA that is used by RNA-guided Cas 
nucleases to cleave the invading nucleic acid in order to protect the cell from 
infection. The acquisition of new spacers allows the CRISPR-Cas immune 
system to rapidly adapt against new threats and is therefore termed ‘adaptation’. 
Recent studies have begun to elucidate the genetic requirements for adaptation 
and have demonstrated that rather than being a stochastic process, the selection 
of new spacers is influenced by several factors. This chapter reviews our current 
knowledge of the CRISPR adaptation mechanism. 
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Chapter 1.1. Overview of CRISPR Immunity 
Bacteria and archaea have evolved to thrive in hostile environments under 
the constant threat of viral (phage) attack. As a result, these organisms have 
devised numerous strategies to prevent phage infection, including abortive 
infection, surface exclusion and restriction modification systems1,2. While highly 
effective, these innate defense strategies provide non-specific immunity. In 
contrast, the CRISPR-Cas immune system provides an adaptive defense 
mechanism against phages and other mobile genetic elements3–5.  
Since their discovery in Escherichia coli in 19876, CRISPR systems have 
proven to be widespread among bacteria and archaea7–9. Generally, a CRISPR 
locus contains the CRISPR-associated (cas) genes and the CRISPR array. The 
cas genes encode a diverse family of Cas proteins carrying predicted functional 
domains of proteins that participate in nucleic acids transactions, such as DNA-
binding proteins, nucleases, polymerases and helicases4,10. The CRISPR array 
consists of identical nonadjacent sequences (repeats) interspaced by similarly 
sized variable sequences (spacers). An AT-rich leader sequence located 
upstream of the first repeat promotes the transcription of the CRISPR array11,12 
and is essential for spacer acquisition. Repeats are usually conserved within the 
same locus, and in most cases contain partially palindromic sequences13. 
Spacers are highly diverse even among closely related strains and were 
therefore initially exploited for strain typing purposes14. In 2005, independent 
bioinformatics studies revealed homology between spacer sequences and mobile 
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genetic elements3,15. This observation led to the hypothesis that CRISPR may 
provide protection against invading phages and plasmids4. Soon, spacers were 
confirmed to provide sequence-specific interference against all prokaryotic routes 
of horizontal gene transfer, including bacteriophage infection5,16,17, plasmid 
conjugation18 and transformation19,20.  
CRISPR-Cas systems provide immunity against phages through a three-
step defense pathway (Figure 1-1). First, a fragment of the invading nucleic acid 
(protospacer) is incorporated into the CRISPR array along with a synthesis of an 
additional repeat unit. This process is known as adaptation and is responsible for 
the unique adaptive features of CRISPR5. Second, during the crRNA biogenesis 
phase, the CRISPR locus is transcribed and then processed into mature guide 
RNAs (crRNAs)21. Third, crRNAs recruit effector complexes and guide them to 
their target by base pairing with the invading nucleic acids22. This last step of 
CRISPR immunity is known as interference and ends with the cleavage of the 
exogenous genetic element23. Despite this general mode of action, CRISPR 
systems have been classified into six types (I-VI), each of them with several 
subtypes, depending on the gene composition and architecture of the 
respective cas operons24,25. While studies of the mechanisms of crRNA 
biogenesis and interference are well advanced, CRISPR adaptation, also known 
as immunization or spacer acquisition, perhaps the most puzzling and fascinating 
aspect of these systems, remains poorly understood. 
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Figure 1-1. The three stages of CRISPR immunity. CRISPR loci consist of 
clusters of repeats (white rectangles) and spacers (colored rectangles) that are in 
proximity of the upstream leader sequence and CRISPR-associated (cas) genes. 
During adaptation, new spacers derived from the genome of the invading virus 
are incorporated into the CRISPR array along with a new repeat unit. During 
crRNA biogenesis, the array is transcribed, and the precursor transcript is 
processed by Cas endoribonucleases in order to generate small crRNAs. During 
interference, the crRNA guides a complex of Cas proteins to the matching target 
to initiate nucleolytic cleavage (scissors) of the invading nucleic acid. 
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Chapter 1.2. Spacer Acquisit ion 
Spacer acquisition was first demonstrated under laboratory conditions in 
2007 for the type II-A system of Streptococcus thermophilus5. In these studies, 
investigators examined the CRISPR array of phage-immunized bacteria and 
found the addition of new repeat-spacer units, with all new spacers perfectly 
matching regions of the genome of the challenging phage. Mutants that acquired 
spacers targeting sequences shared between two phages were resistant to both 
viruses. These results established CRISPR-Cas systems as an adaptive, 
sequence-specific immune system against phages and were corroborated in 
other bacteria and archaea containing different CRISPR-Cas Types: Escherichia 
coli type I-E26–28, Pseudomonas aeruginosa type I-F29, Streptococcus agalactiae 
type II-A30, Haloarcula hispanica type I-B31, and Sulfolobus solfataricus type I-A 
and III-B32.  
Chapter 1.2.1. The Protospacer Adjacent Motif 
When investigators aligned newly acquired spacers from the S. 
thermophilus CRISPR-Cas system in search for common motifs, they found 
something unexpected. Instead of a common sequence within the spacers they 
found a conserved sequence outside the target (also known as protospacer), 
which was termed Protospacer Adjacent Motif (PAM)17. Therefore, it became 
clear early on that not all phage sequences are equal for the CRISPR-Cas 
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system, suggesting that the adaptation machinery only acquires spacers that 
have adjacent PAMs. The PAM is not only important for the acquisition of spacer 
sequences, it is also required for the interference phase of CRISPR immunity 
since PAM mutations in types I and II prevent Cas nuclease cleavage17,33–36. This 
interference requirement is readily exploited by phages, which can avoid CRISPR 
immunity by mutating the PAM sequence17. The PAM is fundamental to avoid 
auto-immunity. If CRISPR immunity relied only on base-pair interactions between 
the crRNA and the target DNA, then the spacer sequence on the CRISPR array 
would be a target for the crRNA as well. Since the flanking sequences of a 
spacer in the CRISPR array are the CRISPR repeat, which lack a proper PAM, 
auto-immunity is prevented and only protospacers that are flanked with the 
correct PAM can be cleaved. Type III CRISPR-Cas systems, however, seem to 
be an exception, as no PAM is evident from the alignment of protospacer 
sequences acquired by these systems, nor it is required for target cleavage37,38. 
As a consequence, Type III systems developed a different mechanism to prevent 
auto-immunity38. 
While the recognition of a PAM by the acquisition machinery is essential 
for a protospacer to be selected, it appears that other mechanisms further 
influence the protospacer choice. Studies of spacer acquisition by the E. coli type 
I-E28,39  and the S. thermophilus type II-A40 CRISPR-Cas systems reported 
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unequal distributions of protospacers across various targets. The expansion of 
the CRISPR arrays from S. thermophilus was monitored using DNA deep-
sequencing upon infection with a lytic phage40 and roughly half a million phage-
derived spacer sequences were analyzed. Surprisingly, the top 10% most 
overrepresented spacers accounted for 99% of the identified sequences. In 
contrast, some candidate protospacers that could have been theoretically 
acquired from the target based on PAM compatibility were never sampled. Due to 
partial sequence similarities between some endogenous spacers and the target, 
Paez-Espino et al.40 propose priming (Figure 1-2a) as a possible explanation for 
the strong overrepresentation of certain protospacers. In a similar study in type I-
E, all potential protospacer sequences adjacent to a PAM were used as spacer 
donors, but the frequencies were indeed highly unequal39. While no correlation 
was observed between the frequency of protospacer incorporation and its 
nucleotide sequence, melting temperature, GC content, ssDNA secondary 
structure, or transcription pattern, other investigators detected additional 
sequence motifs besides the PAM that influence the acquisition efficiency of a 
protospacer41. By exchanging nucleotide blocks of various lengths upstream or 
downstream of one high-acquisition and one low-acquisition protospacer, 
investigators were able to reverse their rates of acquisition, suggesting that DNA 
motifs located at both ends of the highly acquired protospacer were responsible 
for its frequent incorporation. More specifically, in addition to the PAM, a 
dinucleotide AA motif termed Acquisition Affecting Motif (AAM) located at the 3’ 
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end of the protospacer can boost the rate of incorporation of a given protospacer. 
Sequences of more than two million spacers confirmed the overrepresentation of 
the AA motif in highly sampled protospacers. Nonetheless, the AAM was not 
present in all highly sampled protospacers, indicating that other unidentified DNA 
motifs might influence the sampling frequencies of protospacers. In a different 
study, the AAM was not confirmed among plasmid-derived spacers. 
Chapter 1.2.2. Naïve and Primed Acquisit ion 
Cas1 and Cas2 are the only Cas proteins universally conserved across all 
types and subtypes of CRISPR-Cas systems10,24. Initial studies on the role of Cas 
proteins revealed that mutations or deletions of Cas1 and Cas2 did not impact 
interference and crRNA maturation in type I42, type II43,44, and type III45,46. These 
observations led to the hypothesis that the two universal Cas proteins might be 
involved in adaptation. Indeed, in E. coli, overexpression of both cas1 and cas2 
alone in the absence of the other cas genes was sufficient to acquire new 
plasmid-derived or host-derived spacers26,28. Yosef et al. (2012) also found that 
Cas1/2 mediate the preferential acquisition of spacers with a correct PAM, 
demonstrating that there is a mechanism to select spacer sequences flanking 
this motif, as opposed to the random acquisition of DNA sequences followed by 
the selection of those with correct PAMs. The biochemical properties of Cas1 
support its role in spacer acquisition. Pseudomonas aeruginosa Cas1 has been 
shown to bind dsDNA in a sequence-independent manner with high affinity, and 
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to work as a metal-dependent endonuclease which cleaves dsDNA into short 
fragments, that might serve as precursors for new spacers47,48. Nonetheless, it is 
still unclear whether new spacers are cut or copied from the invading molecule. 
Because Cas1 also has the ability to resolve Holliday junctions and thus promote 
DNA integration and recombination events, it could promote the integration of 
spacer sequences into the repeat-spacer array. While many Cas2 crystal 
structures have been solved and studied biochemically49–51, a general consensus 
regarding its activity has not been reached. 
The Cas1/2-mediated acquisition can add repeat-spacer units to a minimal 
CRISPR locus consisting of only one repeat sequence28. This indicates that this 
mechanism of acquisition does not require the presence of any other spacers, i.e. 
a previous exposure to the same or related phages and therefore is referred as 
“naïve” acquisition. This is in contrast to “primed” acquisition, where the presence 
of spacers with a full or partial match to the target DNA increases the frequency 
of acquiring another spacer (Figure 1-2a). 
Primed acquisition has been studied in E. coli, which CRISPR-Cas system 
harbors the genes encoding the Cascade (CRISPR associated complex for 
antiviral defense) complex that contains the crRNA guide and is responsible for 
target recognition42 and the Cas3 nuclease responsible for target cleavage22, in 
addition to Cas1 and Cas2. One study showed that this CRISPR system can 
acquire spacers from a plasmid present in the cell, resulting in plasmid curing27. 
While the acquisition of a single spacer is enough to cure the plasmid, multiple 
Figure 1-2. A model for the acquisit ion of new spacers. (a) 
Naïve vs. primed spacer acquisition. Upon lytic infection with a phage previously 
not encountered, incorporation of a new spacer into the CRISPR array ensures 
cell survival. Only protospacers adjacent to PAMs are sampled. Naïve adaptation 
(left) requires the concerted action of Cas1 and Cas2 alone. Primed acquisition 
(right) presupposes the existence of a non-targeting crRNA with partial homology 
to a region of the infecting phage (purple). Following the low-affinity target 
recognition by the interference machinery, the complex slides along the target 
DNA and, aided by Cas1 and Cas2, and recruits spacers from the same strand at 
a high rate. (b) A model for spacer integration onto the CRISPR array. The 
protospacer (green) is acquired from the viral genome and inserted into the 
CRISPR array at the leader-proximal end. Upon integration, the first pre-existent 
repeat serves as a template for the new repeat. In this model I speculate that the 




spacers were frequently incorporated into the CRISPR array. Interestingly these 
were always acquired from the same strand of DNA. This led to the hypothesis 
that the acquisition of one spacer can trigger the acquisition of additional spacers 
from the same strand of the target DNA27. These authors hypothesize that the 
Cascade complex is directed to bind the foreign nucleic acid by a spacer already 
present in the array. If the match is good enough to trigger interference, Cas3 will 
degrade the dsDNA and these cleavage products can be used by Cas1 and 
Cas2 as precursors for new spacers recruited from the same strand. 
Another study reported primed adaptation during infection of E. coli with 
the M13 phage26. The acquisition of new spacers was much more frequent when 
a spacer already targeting the M13 phage was present in the array. The authors 
showed how the orientation of the priming target determines the orientation of 
new protospacers. Interestingly, priming events occurred when mismatches that 
abolish interference were present between the crRNA and its target. This 
suggests that degradation of the target DNA by CRISPR interference is not 
necessary to prime adaptation. It is hypothesized that the Cascade complex can 
bind an imperfect target and trigger the acquisition of new spacers from the same 
molecule. Mutagenesis of the cas genes showed that in addition to Cas1 and 
Cas2, primed adaptation requires the Cascade complex and Cas3. Subsequent 
high-throughput analysis of spacer acquisition in E. coli confirmed that spacers 
are preferentially acquired from the primed strand with a 10-fold bias39. Assuming 
that spacers acquired from the non-primed strand are due to naïve adaptation, 
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the authors conclude that primed adaptation occurs at much higher rates than 
naïve adaptation. Recently, a comprehensive study performed in type I-E showed 
that priming is nucleotide-dependent, as well as sensitive to the number of 
mutations and their locations with the target. Accordingly, high-throughput 
plasmid-loss assays revealed that priming tolerates up to 13 mutations within the 
PAM and protospacer. While the nucleotide-dependence of priming appears to 
be a more complex mechanism that needs to be further characterized, it appears 
that G-rich spacers are more likely to prime a better adaptation response. 
These observations led to the “sliding” hypothesis for primed acquisition: 
after a low-affinity target recognition by the Cascade-crRNA complex, the 
complex slides along the target DNA randomly stopping at PAM sequences to 
recruit more spacers from the same strand (Figure 1-2a). This hypothesis was 
tested by several studies with results that both corroborated or challenged it. In a 
recent study of the E. coli type I-E system, Savitskaya et al.39 argue that sliding 
from the priming position should lead to a preferential acquisition of nearby 
spacers, producing a gradient in spacer acquisition frequency relative to the 
priming location, which they did not observe. Moreover, insertion of poly-PAM 
blocks on the target molecule next to the priming site failed to halt the putative 
sliding acquisition machinery. Notably, these experiments were carried out on 
rather short (~ 3kb) circular plasmids that might have obstructed acquisition 
gradients caused by the priming site or poly-PAM brakes. In contrast, a recent 
study of Haloarcula hispanica type I-B system showed that protospacers in close-
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proximity of the priming protospacers were sampled more often than 
protospacers located farther away31, thus supporting the sliding hypothesis. 
Regions located both upstream and downstream of the priming protospacer were 
highly sampled, but from opposite strands. Therefore, the authors proposed that 
sliding also involves stochastic Cas3 flipping from one strand of the DNA to the 
other. These contradicting results could be explained either by the presence of 
multiple priming sites or differences in the sliding dynamics, since a fast-sliding 
Cascade would prevent the generation of a positional gradient of acquired 
spacers. 
The priming mechanism has likely evolved as a way to counteract phage 
mutants that escape CRISPR immunity by single point mutations in the target 
sequence. The spacers matching mutated targets cannot direct cleavage but can 
still be used to trigger the acquisition of new spacers and adapt against an 
evolving threat. Furthermore, priming favors the acquisition of multiple spacers 
targeting the same DNA molecule, which reduces the probability of escape and 
strengthens resistance. Notwithstanding the benefits of primed spacer 
acquisition, naïve adaptation remains crucial to detect unknown foreign 
molecules and is probably a universal feature of CRISPR systems. 
Chapter 1.2.3. Spacer Integration 
Once a target has been selected on the invading genome, it has to be 
incorporated into the CRISPR array. During this process, not only the spacer is 
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incorporated, but also a new repeat is added to the array. Spacer insertion is 
polar, since the vast majority of new spacers are incorporated at the 5’ end of the 
array, upstream of the first repeat5,16,52–56. Little is known about this process; 
however, the first repeat and the region immediately upstream of it, known as the 
leader sequence, seem to play a role. 
The 200-500 bp region located upstream of the first repeat contains an 
A/T rich leader sequence that usually harbors the promoter of the CRISPR array, 
but it is also involved in adaptation. Deleting or scrambling the 60 nucleotides 
immediately adjacent to the array of the type I-E CRISPR-Cas system of E. coli 
prevents spacer acquisition28. This indicates that the leader contains specific 
sequence motifs essential for adaptation. Interestingly, deleting the Pribnow box 
required for the transcription of the array does not prevent spacer acquisition28, 
suggesting that transcription is not essential for the adaptation process. It is 
believed that the leader sequence is recognized by the acquisition machinery. 
Evidence supporting this hypothesis comes from a study showing that Cas1 and 
Cas2 from the E. coli K12 strain can direct spacer acquisition in the CRISPR 
array of the O157:H7 strain, which carries a different leader sequence57. 
However, this artificial leader-Cas combination led to frequent abnormal 
acquisition events where the spacers were integrated in the wrong orientation. 
This suggests that the interaction between Cas proteins and the leader sequence 
determines the orientation of newly acquired spacers. Furthermore, in some 
instances, the insertion site was shifted by 2 bases, suggesting that the 
16	
acquisition complex is anchored at the leader-repeat boundary where a first cut is 
made, and uses a ruler mechanism to cut the other strand on the other side of 
the repeat. The nucleotide content of the spacer is also thought to impact the 
orientation of newly acquired spacers. In type I-E, an underrepresentation of G 
and overrepresentation of C at the end of highly acquired spacers may serve as 
signals for insertion in the correct orientation. 
The presence of a single repeat has been shown to be necessary and 
sufficient for both naïve and primed adaptation in the type I-E CRISPR 
system26,58, and the presence of additional repeats does not increase the rate of 
acquisition of new spacers41. Interestingly, spacers incorporated into a minimal 
CRISPR array (one repeat, no preexisting spacers) have the correct length58, 
suggesting that the protein machinery, rather than preexistent repeat-spacer 
units, dictates the size of additional spacers. In type I-E systems, the new repeat 
(29 nt long) is copied from the first repeat in the array since point mutations 
introduced in the first repeat are replicated in newly incorporated spacer-repeats 
units26,28. Interestingly, mutations of the last nucleotide of the repeat were not 
passed on to new repeats, indicating that only bases 1 through 28 of the repeat 
serve as a template for new repeats. In contrast, the 29th base originates from the 
protospacer and represents the last nucleotide of the PAM26,59. While the last 
nucleotide of the 5’-AWG-3’ PAM is highly conserved in E. coli, this is not the 
case in many other systems where this mode of repeat duplication remains to be 
determined. Based on these results and on the known mechanisms of insertion 
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of transposable elements60 and retroviruses61 a model for spacer acquisition has 
emerged (Figure 1-2b). The first repeat sequence of the CRISPR locus is 
subjected to ssDNA nicking at the 3’ end of each repeat strand. This cleavage 
could be facilitated by the stem-loop structure that can form on most repeats due 
to their partially palindromic sequences. Proximity to the leader would provide 
recognition of the first repeat and/or help recruit the spacer acquisition 
machinery. The free 3’-ends of repeats are ligated to the 5’ end of viral 
fragments, leading to the insertion of a new spacer and the generation of a 
staggered intermediate. The gaps are filled by DNA polymerase I, thus adding a 
new repeat to the array. Current research across different laboratories is testing 
this model. 
Chapter 1.3. Unanswered Questions 
Although recent studies have established molecular requirements as well 
as a general mechanism for the acquisition phase, many details of CRISPR 
adaptation are still poorly understood. An extra layer of complexity is added by 
the many different types of CRISPR-Cas systems, some of which could have 
different mechanisms of spacer acquisition. Indeed, variations in the way spacers 
are acquired from the target likely exist between CRISPR types and subtypes. In 
the type I-A of the crenarchaeon Thermoproteus tenax, Cas1 and Cas2 are fused 
as a single protein that forms the CRISPR-associated complex for the integration 
of spacers (Cascis) together with Csa1 and Cas462. In type II, Csn2 was reported 
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to be required for adaptation5. Structural studies have revealed that this protein 
forms a ring-like structure around DNA, suggesting that it might recruit other 
proteins to the protospacer and could form a sliding clamp that facilitates primed 
acquisition63. In type III, interference is transcription dependent and requires 
crRNAs that are antisense to their cognate RNA targets64. Since transcription of 
CRISPR loci is unidirectional, type III spacers need to be incorporated into the 
correct orientation in order to produce functional crRNAs. The underlying 
mechanism of this requirement is not understood. 
I believe that future research will focus on understanding how the leader 
sequence is recognized, how the first repeat is cleaved, and the new spacer 
ligated in a way that allows the generation of an additional repeat, and whether 
the length of the array is regulated. In addition, it is still unknown why spacers are 
acquired preferentially from certain molecules or certain positions on a given 
molecule, and whether any mechanisms truly exist to prevent, or at least limit, the 
 of self-targeting spacers. An interesting question also arises from the 
observation that the PAM motif is recognized both during acquisition and 
interference, and that the motif might be recognized by different protein 
complexes in each of these stages of the CRISPR immunity pathway. As the 
exact sequence requirements might be different for these two functions, it has 
been proposed to use the term Spacer Acquisition Motif (SAM) when referring to 
the sequence recognized by the acquisition machinery and the term Target 
Interference Motif (TIM) when referring to the sequence recognized by the 
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interference machinery65. A mutation that affects SAM recognition might lead to 
the acquisition of spacers that will not be effective during the interference stage. 
Conversely, a mutation that affects the TIM recognition might render preexisting 
as well as newly acquired spacers useless. In the presence of this apparent 
evolutionary bottleneck, PAM sequences might be expected to be highly 
conserved, yet an extensive diversity has been described. How these two facts 
can be reconciled remains to be investigated. 
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Chapter II.  
The Role of Cas9 in Spacer Acquisit ion 
This chapter investigates the molecular requirements of spacer 
acquisition in the type II-A CRISPR system of Streptococcus pyogenes. Cas9 
cleavage of the viral genome requires the presence of a 5′-NGG-3′ 
protospacer adjacent motif (PAM) sequence immediately downstream of the 
viral target. It is not known whether and how viral sequences flanked by the 
correct PAM are chosen as new spacers. Here I show that Cas9 selects 
functional spacers by recognizing their PAM during spacer acquisition. The 
replacement of cas9with alleles that lack the PAM recognition motif or 
recognize an NGGNG PAM eliminated or changed PAM specificity during 
spacer acquisition, respectively. Cas9 associates with other proteins of the 
acquisition machinery (Cas1, Cas2 and Csn2), presumably to provide PAM-
specificity to this process. This chapter introduces a new function for Cas9 in 
the genesis of prokaryotic immunological memory. 
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2.1. The Protospacer Adjacent Motif is Highly Conserved 
Based on their cas gene content, CRISPR-Cas systems can be classified 
into six distinct types, I-VI24,25. Each CRISPR-Cas type possesses different 
mechanisms of crRNA biogenesis, target destruction and prevention of 
autoimmunity. In the type II CRISPR-Cas system present in Streptococcus 
pyogenes the Cas9 nuclease inactivates infective phages using crRNAs as 
guides to introduce double-strand DNA breaks into the viral genome23. Cas9 
cleavage requires the presence of a protospacer adjacent motif (PAM) sequence 
immediately downstream of the protospacer34,67. This requirement avoids the 
cleavage of the spacer sequence within the CRISPR array, i.e. autoimmunity, 
since the adjacent repeat lacks a PAM sequence. The importance of the PAM 
sequence for target recognition and cleavage34,67–69 suggests the presence of a 
mechanism to ensure that newly acquired spacer sequences match protospacers 
flanked by a proper PAM sequence. For the type I-E CRISPR-Cas system of 
Escherichia coli, over-expression of cas1 and cas2 is sufficient for the acquisition 
of new spacers in the absence of phage infection. Reports indicate that spacers 
acquired in this fashion match preferentially (25–70%, depending on the study) to 
protospacers with the correct PAM (AWG, W=A/T)26,28,57,70, suggesting that Cas1 
and Cas2 are sufficient for spacer acquisition and have some intrinsic ability to 
recognize protospacers with the right PAM. In the type II system of S. pyogenes 
the PAM sequence is NGG (and also NAG at a much lower frequency)4,33,34, 
where N is any nucleotide, and it is recognized and bound by a domain within the 
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Cas9 tracrRNA:crRNA-guided nuclease during target cleavage67,71. How spacers 
are acquired in this system, particularly how spacers with correct PAM 
sequences are selected during this process, is not known. 
2.2. Cas9 is required for spacer acquisit ion 
To investigate the mechanisms of recognition of PAM-adjacent 
protospacers during spacer acquisition, Icloned the type II-A CRISPR-Cas locus 
of S. pyogenes (Figure 2-1a) into the staphylococcal vector pC194 and 
introduced the resulting plasmid64 into Staphylococcus aureus RN422072, a strain 
lacking CRISPR-Cas loci. Ichose this experimental system because it facilitates 
the genetic manipulation of the S. pyogenes CRISPR-Cas system. Ifirst tested 
the ability of the cells to mount adaptive CRISPR immunity by infecting them with 
the staphylococcal phage ϕNM4γ4, a lytic variant of ϕNM473 (see Methods for a 
description of ϕNM4γ4 isolation).  
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Figure 2-1. Cas9 is required for spacer acquisit ion. (a) Organization of 
the S. pyogenes type II-A CRISPR-Cas locus. Arrows indicate the annealing 
position of the primers used to check for the expansion of the CRISPR array. (b) 
PCR-based analysis of cultures to check for the acquisition of new spacer 
sequences. In the presence or the absence of phage φNM4γ4 infection. Wild-type 
(WT) as well as different cas mutants were analyzed. MOI; multiplicity of 
infection. (c) Cultures over-expressing Cas1, Cas2 and Csn2 under the control of 
a tetracycline-inducible promoter were analyzed using PCR for spacer acquisition 
in the absence of phage infection. The strain was complemented with plasmids 
carrying either Sp or St Cas9 (see Fig. S3). aTc; anhydrotetracycline. 
Plate-based assays performed by mixing bacteria and phage in top agar 
allowed the selection of phage-resistant colonies that were checked by PCR to 
look for the expansion of the CRISPR array (Figure 2-2a). On average 50 % of 
the colonies acquired one or more spacers (8/13, 5/11 and 7/16 in three 
independent experiments), whereas the rest of the resistant colonies survived 
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million reads detected protospacers adjacent to 2083 out of 2687 NGG 
sequences present in the viral genome, although with variation in the frequency 
of acquisition of each sequence (Figure 2-2b). The data revealed a prominent 
selection of spacers matching protospacers with downstream NGG PAM 
sequences (99.97 %, Figure 2-2c). The acquisition of new spacers by cells in 
liquid culture proved to be simple and highly efficient, providing the possibility to 
look at millions of new spacers in a single step. It was therefore implemented in 
the rest of our studies. 
To determine the genetic requirements for spacer acquisition Imade 
individual deletions of cas1, cas2 or csn2 and challenged the mutant strains with 
phage ϕNM4γ4. Spacer acquisition was decreased to levels below our limit of 
detection in each of these mutants (Figure 2-1b), corroborating previous 
experiments26,43. Therefore, while Cas1, Cas2 and Csn2 are dispensable for anti-
phage immunity in the presence of a pre-existing spacer (Figure 2-3b and c), 
they are required for spacer acquisition. 
phage infection by a non-CRISPR mechanism, most likely including phage 
receptor mutations (Figure 2-3a). To maximize the capture of new spacer 
sequences, Iperformed the same assay in liquid and recovered surviving bacteria 
at the end of the phage challenge. These were analyzed by PCR of the CRISPR 
array and the amplification products of expanded loc I was subjected to Illumina 
MiSeq sequencing to determine the extent of spacer acquisition. Analysis of 2.96 
Figure 2-2. The S. pyogenes type II CRISPR–Cas system displays a 
strong bias for the acquisit ion of spacers matching viral 
protospacers with NGG PAMs. (a) Analysis of bacteriophage-insensitive 
mutant colonies using PCR and agarose gel electrophoresis, representative of 
five technical replicates. Bacteria and phage were mixed in top agar and 
incubated overnight. DNA was isolated from individual colonies resistant to 
phage infection and used as template for a PCR reaction with primers (arrows) 
H182 and H183, which amplify the end of the S. pyogenes CRISPR array. The 
size of the PCR band indicates the number of new spacers (shown at the top of 
the gel). Cells without additional spacers resist infection by a CRISPR-
independent mechanism, presumably envelope resistance. (b) Analysis of 
acquired spacers during phage infection of a population of bacteria carrying the 
S. pyogenes type II CRISPR–Cas system. Liquid cultures of bacteria were 
infected with phage, surviving cells were collected at the end of the infection, 
DNA extracted and used as template for a PCR reaction as described above. 
Amplification products were separated by agarose gel electrophoresis and the 
DNA of the bands corresponding to products with additional spacers was 
extracted and sent for MiSeq next generation sequencing. Reads corresponding 
to newly acquired spacers were plotted according to their position in the phage 
genome (x axis) and their abundance (y axis). Each dot represents a unique 
spacer sequence; blue and red dots indicate a corresponding protospacer with 
an NGG or non-NGG PAM. Top and bottom plots indicate protospacers in the top 
and bottom strands of the viral DNA. The map as well as the different functions of 
the phage genes are indicated in between the plots. (c) Weblogo showing the 
conservation of the 59 flanking sequences of 10,000 protospacers randomly 
selected from the experiment shown in b. Absolute conservation of the NGG 




Figure 2-3. Cas1, cas2 and csn2 are not required for the execution 
of immunity. (a) Analysis of bacteriophage-resistant mutants that do not 
acquire a new spacer. Three colonies that survived phage infection in our in-plate 
adaptation assay (Figure 2-2) were subjected to phage adsorption assay. Briefly, 
surviving colonies as well as the wild-type S. aureus RN4220 control were grown 
in liquid and mixed with bacteriophage. After a brief incubation, cells were 
pelleted by centrifugation and the phages present in the supernatant (unable to 
bind and infect cells) were counted on a lawn of sensitive cells. The number of 
plaque-forming units (p.f.u.) of a control experiment in the absence of host cells 
were used to determine the 100% free phage, or 0% adsorption value. No 
plaques were observed in the control experiment using wild-type cells and this 
value was used to set the 100% adsorption limit. The three CRISPR-
independent, bacteriophage-resistant mutants displayed a marked defect in 
phage adsorption (about 50%), indicating that most likely they carry envelope 
resistance mutations. (b) cas1, cas2 and csn2 are not required for the execution 
of immunity using previously acquired spacers. Position within the phage NM4 
genome of the type II CRISPR–Cas target used in this experiment. The 
protospacer sequence is in the bottom strand (shown in 3’–5’ direction) and 
flanked by a TGG PAM (in green). (c) Comparison of immunity provided by a 
type II CRISPR–Cas system programmed to target the sequence shown in panel 
(a) in the presence (wild-type, wt) or absence (dcas1,dcas2, dcsn2) of cas1, 
cas2 and csn2. Immunity is measured as the p.f.u. of a phage lysate spotted on 
top agar lawns of S. aureus RN4220 cells containing no CRISPR system, a wild-
type S. pyogenes CRISPR–Cas type II system (wt, pRH233), or the same 
CRISPR–Cas systems with a deletion of cas1, cas2 and csn2 genes (dcas1, 
dcas2, dcsn2, pRH079). 
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To determine whether these genes are also sufficient for this process, 
Iover-expressed cas1, cas2 and csn2 in the absence of cas9 using a 
tetracycline-inducible promoter in plasmid pRH223 and looked for the integration 
of new spacers in the absence of phage infection using a highly sensitive PCR 
assay (Figure 2-4). Iwere unable to detect new spacers even in the presence of 
the inducer (Fig. 2-1c). However, the addition of a second plasmid expressing 
tracrRNA and Cas9 from their native promoters (Figure 2-4a) enabled spacer 
acquisition only in the presence of the inducer, with all the new spacers matching 
chromosomal or plasmid sequences (Figure 2-1c). Although most likely the 
acquisition of such spacers causes cell death or plasmid curing, respectively, the 
acquisition event can still be detected in liquid culture using our highly sensitive 
PCR assay (Figure 2-4b and c). The tracRNA (Figure 2-1a) is a small RNA 
bound by Cas9 that is required for crRNA processing and Cas9 nuclease activity. 
Iwondered if Cas9 involvement in spacer acquisition also required the presence 
of the tracrRNA. Deletion of the tracrRNA prevented spacer acquisition in the 
absence of phage infection (Figure 2-1c), suggesting that apo-Cas9 is not 
sufficient to promote spacer acquisition and that association with its cofactor is 
also required. Altogether these data indicate that Cas1, Cas2 and Csn2 are 
necessary but not sufficient for the incorporation of new spacers and that 
tracrRNA/Cas9 is also required. This is in contrast to the type I-E CRISPR-Cas 
system of E. coli, where over-expression of Cas1 and Cas2 alone is sufficient for 
spacer acquisition. It is important to note that the CRISPR array used in this 
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assay consists of a single repeat, without pre-existing spacers (Figure 2-4). 
Therefore, the Cas9 requirement is not a consequence of the phenomenon 
known as “primed” spacer acquisition. This refers to an increase in the frequency 
of spacer acquisition observed in type I CRISPR-Cas systems that relies on the 
presence of a pre-existing spacer with a partial match to the phage genome as 
well as the full targeting complex (Cascade)26,31,74. 
contains cas1, cas2 and csn2 from S. pyogenes under a tetracycline-inducible 
promoter. Cells containing this plasmid only acquired spacers when a second 
plasmid expressing cas9 was introduced, pRH240 or pRH241, containing the 
tracrRNA gene, the leader and first repeat from the S. pyogenes type II CRISPR–
Cas system as well as cas9 from S. pyogenes (cas9Sp) or S. thermophilus 
(cas9St), respectively. The leader is a short, AT-rich sequence immediately 
upstream of the first repeat that contains the promoter for the transcription of the 
CRISPR array. (b) Highly sensitive PCR assay to enrich for amplification 
products of adapted CRISPR loci. Arrows indicate primer annealing position and 
direction. The forward primer (JW8) anneals on the leader. For the reverse 
primer, a cocktail of JW3, JW4 and JW5 was used. The three reverse primers 
anneal on the repeat and differ only in their 3’-end nucleotide that never matches 
the last nucleotide of the leader (red arrowhead). Because this nucleotide is 
critical for the annealing of the primers, loci that acquire spacers ending in A, C or 
T are preferentially amplified over unadapted loci. (c) To quantify the sensitivity 
of this technique, Imixed pGG32 (one repeat, unadapted) with pRH087 (repeat-
spacer-repeat, adapted) in known ratios. The amplification of adapted plasmid 
was detected even when it represented 0.01% of the total plasmid template, 
representative of three technical replicates. This highly sensitive PCR assay is 
not required to detect acquisition during phage infection, as in this case adapted 
cells survive and are enriched within the population, making their detection much 
easier. 
Figure 2-4. Generation of an experimental system for the 
overexpression of cas1, cas2 and csn2 and the detection of spacer 
acquisit ion in the absence of phage infection. (a) Plasmids used in the 




2.3. Cas9 specif ies the PAM sequence of newly acquired spacers 
Given this newfound requirement in the CRISPR adaptation process and 
the well-established PAM recognition function of Cas9 during the surveillance 
and destruction of viral target sequences, I hypothesized that this nuclease could 
participate in the selection of PAM sequences during spacer acquisition. To test 
this I exchanged the cas9 genes of S. pyogenes (Sp) and S. thermophilus (St) 
CRISPR-Cas systems to create two chimeric CRISPR loci: tracrRNASp-cas9St-
cas1Sp-cas2Sp-csn2Sp and tracrRNASt-cas9Sp-cas1St-cas2St-csn2St (Figure 2-6a). I 
chose the type II-A CRISPR-Cas system of S. thermophilus (also known as 
CRISPR3) because it is an ortholog of the S. pyogenes system75. While the PAM 
sequence for the Sp CRISPR-Cas system is NGG, the PAM sequence for the St 
system is NGGNG16 (Figure 2-6b). I infected each naïve strain with phage 
ϕNM4γ4, sequenced the newly acquired spacers, and obtained the PAM of the 
matching protospacers using WebLogo76. I found that each chimeric system 
acquired spacers with PAMs that correlated with the cas9, but not the tracrRNA, 
cas1, cas2 or csn2, allele present (Figure 2-6b). To rule out the possibility that 
non-functional spacers are negatively selected during phage infection, i.e. they 
are acquired randomly and only those cells containing spacers with a correct 
PAM for Cas9 cleavage provide immunity and allow cell survival, I sequenced the 
PAMs of spacers acquired in the absence of phage infection (Fig. 2-1c and 2-6c). 
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Either Cas9Sp or Cas9St were produced in cells overexpressing Cas1Sp, Cas2Sp 
and Csn2Sp. In this experiment, as explained above, spacers matching 
chromosomal or plasmid sequences will be acquired. The PCR products 
containing new spacers were cloned into a commercial vector from which they 
were sequenced. Expression of Cas9Sp led to the incorporation of spacers 
matching protospacers with an NGG PAM sequence, whereas the expression of 
Cas9St in the same cells shifted the composition of the PAM to NGGNG (Fig. 2-
6d). These results demonstrate that Cas9 specifies PAM sequences to ensure 
the acquisition of functional spacers during CRISPR adaptation. 
Figure 2-6. Cas9 determines the PAM sequence of acquired 
spacers. (a) (c) Genetic composition of the CRISPR–Cas loci tested for spacer 
during phage infection (a), or in the absence of infection (c), with the 
experimental set up shown in Figure 2-4. (b) (d) Sequence logos obtained after 
the alignment of the 3’ flanking sequences of the protospacers matched by the 
newly acquired spacers in panels (a) and (c) respectively. Numbers indicate the 
positions of the flanking nucleotides downstream from the spacer. Number of 
sequences used in each alignment indicated as n. 
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2.4. Cas9 associates with other Cas proteins involved in spacer 
acquisit ion 
In type I CRISPR-Cas systems, Cas1 and Cas2 form a complex70 and the 
dsDNA nuclease activity of Cas1 has been implicated in the initial cleavage of the 
invading viral DNA to generate a new spacer48. The genetic analyses presented 
above suggest that in the type II S. pyogenes CRISPR-Cas system, the PAM-
binding function of Cas9 observed in vitro67 could specify a PAM-adjacent site of 
cleavage for Cas1, or other members of the spacer acquisition machinery. This 
would guarantee that newly acquired spacers have the correct PAM needed for 
Cas9 activity later in this immune pathway. This hypothesis predicts an 
interaction between Cas9 and Cas1, Cas2 and/or Csn2. To test this, I expressed 
the type II Cas operon in E. coli, using a histidyl tagged version of Cas9, and 
looked for other proteins that co-purify. I observed an abundant co-purifying 
protein with an apparent molecular weight close to 33 kDa, the expected size of 
Cas1 (Figure 2-5). 
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Figure 2-5. Purif ication of a Cas9–Cas1–Cas2–Csn2 complexes. (a) 
The cas9–cas1–cas2–csn2 operon of S. pyogenes SF370 was cloned into the 
pET16b vector (generating pKW07) to add an N-terminal histidyl tag to Cas9 and 
express all proteins in E. coli. Purification was performed using Ni-NTA affinity 
chromatography. SDS–PAGE followed by Coomassie staining of the purified 
proteins revealed a co-purifying protein that was identified as Cas1 by mass 
spectrometry, in a result representative of five technical replicates. (b) The cas9–
cas1– cas2–csn2 operon of S. pyogenes SF370 was cloned into the pET23a 
vector (generating pKW06) to add a C-terminal histidyl tag to Csn2 and express 
all proteins in E. coli. Purification was performed using Ni-NTA affinity 
chromatography followed by ion exchange chromatography. The elution fractions 
that constituted the peak containing the complex (Figure 2-7a) were separated by 
SDS–PAGE and visualized 
Mass spectrometry confirmed the identity of both of these proteins as well 
as the presence of Cas2 and Csn2 co-purifying with Cas9 (Table 1). This result 
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suggested the formation of a Cas9-Cas1-Cas2-Csn2 complex and therefore I 
explored other purification strategies to unequivocally determine its existence.  I 
was able to isolate a Cas9-Cas1-Cas2-Csn2 complex when the histidyl tag was 
added to Csn2 (Figure 2-7a and b). The identity of the purified proteins was 
confirmed by mass spectrometry (Table 2). This demonstrates a biochemical link 
between the Cas9 nuclease and the other Cas proteins that function exclusively 
to acquire new spacers, supporting the role of Cas9 as a PAM specificity factor in 
the adaptation phase of CRISPR immunity. 
Table 1. Mass spectrometry analysis of proteins purif ied through Ni-
NTA 
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Table 2. Mass spectrometry analysis of protein bands from the 
purif ied Cas9–Cas1–Cas2–Csn2 complex 
Figure 2-7. S. pyogenes Cas9 PAM recognit ion domain is required 
for the acquisit ion of spacers with an NGG PAM sequence. (a) 
Separation of the Cas9–Cas1–Cas2–Csn2 complex by ion exchange 
chromatography. (b) SDS– PAGE of fraction 19 (peak) from the complex elution 
shown in panel (a), representative of five technical replicates. The four proteins of 
the complex were individually purified and run alongside the purified fraction to 
identify each protein in the complex. (c) Spacer acquisition was tested as in 
Figure 2-1c in the presence or absence of different Cas1 or Cas9 activities. 
Image is representative of eight technical replicates. dCas1, nuclease-dead Cas1 
(E220A mutation); dCas9, nuclease-dead Cas9 (D10A, H840A mutations); 
Cas9PAM lacks the PAM recognition function (R1333Q, R1335Q mutations). (d) 
Sequence logos obtained after the alignment of the 39 flanking sequences of the 
protospacers matched by the newly acquired spacers in panel (c). Numbers 
indicate the positions of the flanking nucleotides downstream from the spacer. 




Cas1, Cas1E220A (catalytically dead or dCas148), wild-type Cas9, Cas9D10A,H840A
(catalytically dead or dCas934) and Cas9R1333Q,R1335Q (Cas9PAM, containing 
mutations in the PAM-binding motif that substantially reduces binding to target 
DNA sequences with NGG PAMs in vitro71). I observed that the nuclease activity 
of Cas1 is necessary for spacer acquisition (Figure 2-7c). In contrast, the 
nuclease activity and PAM-binding function of Cas9 are dispensable for this 
process. Next I determined the PAM of the acquired spacers in the presence of 
mutated Cas9 (Figure 2-7). I found that whereas spacers acquired in the 
presence of dCas9 displayed correct PAMs, those acquired in the presence of 
Cas9PAM matched DNA regions without a conserved flanking sequence, i.e. 
without a PAM sequence. The same result was obtained with St dCas9 (Figure 2-
8). Altogether these results indicate that Cas1 and Cas9 are part of a complex 
dedicated to spacer acquisition which requires Cas1 nuclease activity and Cas9 
PAM-binding properties for the selection of new spacer sequences. 
2.5. The PAM binding motif of Cas9 is required for PAM selection 
Within this complex the PAM-binding domain of Cas9 would specify a 
functional spacer (one adjacent to a correct PAM) and the nuclease activity of 
Cas1 and/or Cas9 would cleave the invading DNA to extract the spacer 
sequence. To test this I performed adaptation studies in the absence of phage 
selection as described in Figure 2-4 but using different combinations of wild-type 
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Figure 2-8. dCas9St can also support spacer acquisit ion. A plasmid 
derived from pRH241 containing mutations in the active site of S. thermophilus 
Cas9 (D10A, H847A; dCas9St) was used to characterize spacer acquisition in 
the absence of phage infection. Upon overexpression of Cas1, Cas2 and Csn2 
using anydrotetracycline (aTc), I was able to detect spacer acquisition. 
Sequencing of spacers and alignment of the protospacer flanking sequences 
demonstrated the selection of an NGGNG PAM. The image is representative of 
three technical replicates. 
2.6. Discussion 
The selection of new spacers with a correct PAM is fundamental for the 
survival of the infected host during CRISPR-Cas immunity. In the simplest 
scenario there is no active selection of PAM-flanked protospacers; any spacer 
sequence can be acquired but only those with the correct PAM allow Cas9 
cleavage of the invader and survival. Bacteria that acquire spacers with 
ineffective flanking sequences are killed by the virus and as a consequence 
PAM-flanking spacers are enriched in the population. Here I show that even in 
the absence of phage selection, the type II CRISPR-Cas system acquires new 
spacers with correct PAMs, a result that rules out the possibility of random 
spacer selection with subsequent selection for functional spacers. How are PAM-
flanked protospacers selected during type II CRISPR-Cas immunity? One 
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possibility is that the proteins exclusively dedicated to spacer acquisition perform 
the PAM-selection function. The inability of cells over-expressing only cas1, cas2 
and csn2 to expand the CRISPR array strongly suggest that none of the proteins 
encoded by these genes can recognize and select correct PAMs. Another 
possibility is that the known PAM recognition function of Cas971,77, essential for 
destroying the invading virus, could also be used during spacer acquisition to 
recognize PAM-flanking viral sequences. Experiments showing that the cas9 
allele, but not the cas1-cas2-csn2 alleles, determine the PAM sequence of the 
newly acquired spacers, demonstrated that this scenario is likely correct. How 
does Cas9 select new spacers with the correct PAMs? Our experiments 
demonstrate that Cas9 forms a stable complex with Cas1, Cas2 and Csn2 that 
presumably participates in the selection of new spacers. 
The nuclease activity of Cas1, but not of Cas9, is required for spacer 
acquisition. The tracrRNA is also required, suggesting that the apo-Cas9 
structure77, very different from holo-Cas971, does not have the correct 
conformation to participate in spacer acquisition. The key residues involved in 
Cas9 PAM recognition are not required for spacer acquisition, but they are 
necessary for the incorporation of new spacers with the correct PAM sequence. 
This suggests that the reported non-specific DNA binding property of Cas934,67 is 
sufficient for spacer acquisition, but not for the selection of functional spacers. 
There are currently two models for the incorporation of new spacers into the 
CRISPR array, one where the future spacer sequence is cut from the invading 
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viral DNA, the “cut and paste” model, and another where this sequence is copied 
from the viral genome, the “copy and paste” model78. In the context of the first 
model, our data suggests that, at a low frequency that may reflect the dynamics 
of spacer acquisition, Cas1 cleaves the invading genome to extract a new spacer 
sequence. However, on its own, Cas1 nuclease activity is non-specific48. 
Therefore, I propose that through the formation of the Cas9-Cas1-Cas2-Csn2 
complex, Cas9 binding to PAM-adjacent sequences provides specificity to Cas1 
endonuclease activity. In the “copy and paste” model, Cas1 nuclease activity is 
most likely necessary for downstream events, such as the cleavage of the repeat 
sequence that precedes spacer insertion, and Cas9 is required to “mark” 
sequences adjacent to GG motifs to be copied into the CRISPR array. In any 
case, following yet unknown processing and integration events, the selected DNA 
becomes a new functional spacer, i.e. its matching protospacer will have the 
correct PAM to license Cas9 cleavage (Figure 2-9). The molecular steps that 
take place after protospacer selection to incorporate it as a new spacer in the 
CRISPR array are still unknown. All genes of the type II-A CRISPR-Cas locus 
(tracrRNA, cas9, cas1, cas2 and csn2) are required for spacer acquisition, 
therefore most likely all the members of the Cas9-Cas1-Cas2-Csn2 complex 
participate in the process. Future work will address this and other aspects of the 
mechanisms of spacer integration in different CRISPR-Cas systems. 
The present chapter reveals a new function for Cas9 in CRISPR immunity. 
This nuclease is fundamental for both the execution of immunity, participating in 
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the surveillance and destruction of infectious target viruses, and the generation of 
immunological memory, selecting the viral sequences that allow adaptation and 
resistance to viral predators. 
Figure 2-9. A model for the selection of PAM-flanking spacers by 
Cas9. After injection of the phage DNA, an adaptation complex formed by Cas9, 
Cas1, Cas2 and Csn2 uses the Cas9 PAM binding domain to specify functional 
protospacers, that is, that are followed by the correct PAM. It is not known how 
the protospacer sequence is extracted from the viral DNA to become a spacer. In 
the ‘cut and paste’ model, a nuclease, possibly Cas1, cuts the viral DNA to 
generate the spacer. In the ‘copy and paste’ model the protospacer sequence is 
copied first. Once loaded with the selected protospacer sequence, this complex 
promotes the integration of this sequence into the CRISPR array, thus becoming 
a new spacer. Previous studies demonstrated that Cas1 dimerizes and interacts 
with Cas270, Csn2 has been determined to forma tetramer63. 
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Chapter III .  
Generation of Cas9 Variants that 
Increase Spacer Acquisit ion 
Having learned that Cas9 participates in spacer acquisition by specifying 
functional viral targets, I wanted to further explore this topic by engineering Cas9 
mutants that provide enhanced CRISPR immunity. Here I performed random 
mutagenesis of the RNA-guided Cas9 nuclease to look for variants that provide 
enhanced immunity against viral infection. I identified a mutation, I473F, which 
increases the rate of spacer acquisition by more than two orders of magnitude. 
The results presented in this chapter highlight the role of Cas9 during CRISPR 
immunization and provide a useful tool to study this otherwise rare process and 
develop it as a biotechnological application. 
3.1 Changing the PAM specif icity of Cas9 
Based on their cas genetic repertoire, CRISPR-Cas systems have been 
classified into six types, I through VI24,83. Cas9 is the crRNA-guided nuclease of 
the type II-A CRISPR-Cas system of Streptococcus pyogenes34. In addition to 
protospacer recognition by the crRNA, Cas9 target cleavage requires a 5’-NGG-
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3’ protospacer adjacent motif (PAM) immediately downstream of the 
target17,33,34,71. Cas9 is also required for the immunization step of the CRISPR 
response84,85, using its PAM binding domain to specify functional spacer 
sequences that are flanked by the required NGG motif84. In support of its role in 
spacer acquisition, Cas9 can associate in vivo with the other proteins encoded by 
the type II-A CRISPR-Cas system: Cas1, Cas2 and Csn284. 
To further study the role of Cas9 in spacer acquisition, I decided to change 
its PAM specificity. Earlier work from our lab tested in vivo cleavage of targets 
having the same protospacer sequence but different PAMs displaying all possible 
trinucleotide combinations. I found that, in addition to the complete cleavage of 
targets with NGG PAMs, wild-type Cas9 displays approximately 50% of in vivo 
cleavage of targets with NAG PAMs. In an effort to understand how Cas9 affects 
the acquisition of spacers flanked by NGG motifs, I decided to evolve this weak 
but detectable affinity of the nuclease for NAG PAMs. After structural analysis 
determined the PAM interacting domain of Cas971,77, different groups have 
specifically mutated this domain to obtain a versatile set of nucleases for genome 
editing purposes and have obtained an NAG-recognizing Cas986. I took a 
different approach and searched for mutations in any region of the nuclease that 
would increase its specificity for NAG-flanked targets. I found one such mutation, 
I473F, which provided partial immunity when directed (programmed) to recognize 
an NAG viral protospacer. Importantly, this mutation also expanded the levels of 
the CRISPR-Cas adaptive immune response, increasing the number of CRISPR-
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mediated, bacteriophage-resistant colonies by more than two orders of 
magnitude. I performed experiments to understand the molecular basis of the 
enhanced CRISPR-Cas immunity and determined that the I473F mutation 
mediates a significant increase in spacer acquisition. Our results highlight the 
role of Cas9 during CRISPR immunization and provide a useful tool to study this 
otherwise rare process. 
3.2. Evolved Cas9 has increased NAG PAM specif icity 
S. pyogenes Cas9 has an innate ability to cleave NAG-adjacent targets, 
but with much lower efficiency than it cleaves canonical (NGG) targets33. To 
enhance the ability of the nuclease to target protospacer sequences flanked by 
NAG PAMs, I constructed a library of plasmids carrying mutagenized cas9 
variants by subjecting the entire gene to error-prone PCR (Figure 3 -1a). The 
library plasmids also harbor the trans-activating crRNA (tracrRNA) gene44 and a 
single-spacer CRISPR array targeting a protospacer sequence 
(AAAAACAAAAATGTTTTAACACCTATTAACG) followed by a TAG PAM on the 
genome of the lytic staphylococcal bacteriophage ϕNM4γ464. The library was 
transformed into Staphylococcus aureus RN4220 cells that were subjected to 
phage infection on soft-agar plates to select for phage-resistant bacterial 
colonies. These colonies originated either from cells that acquired surface 
mutations preventing phage adsorption or cells harboring mutant cas9 alleles 
with improved NAG cleaving efficiency that can sustain anti-viral immunity. To 
enrich for bacteria harboring desired Cas9 mutants, I isolated and re-transformed 
the plasmids of surviving colonies to perform a second round of phage infection. 
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Several colonies were obtained, and I proceeded with a further analysis of one of 
the “evolved” mutants that gained phage resistance. Sequencing of the plasmid 
revealed the presence of six single-nucleotide substitutions in the cas9 gene, 
producing the following missense mutations: R425G, I473F, K500I, S701G, 
P756L and A1032G. 
To evaluate the importance of each of these mutations in the gain-of-
function phenotype I introduced them individually into the cas9 gene and tested 
the ability of the resulting plasmid to prevent ϕNM4γ4 propagation by measuring 
the number of plaque forming units (pfu) that result after infection of the host cells 
(Figure 3-1b). Whereas cells harboring a control vector do not provide any 
immunity and allow high levels of phage propagation (up to ~1010 pfu/ml), cells 
containing wild-type Cas9 provide partial immunity and reduce phage 
propagation by about two orders of magnitude. Cas9 harboring the R425G, 
S701G, P756L and A1032G mutations allow wild-type levels of phage 
propagation and therefore do not contribute to the gain-of-function-phenotype of 
the evolved cas9 allele I isolated. In contrast, cells containing Cas9 with the 
I473F or K500I mutations decrease phage propagation by about four orders of 
magnitude. This is close to the levels of immunity provided by wild-type Cas9 
when programmed against NGG-flanked targets (a reduction of ~ 5 orders of 
magnitude, see Figure 3-3b). Similar results were obtained when other NAG 
PAMs were used in this assay (AAG, CAG, GAG, Fig. S1). Therefore, the I473F 
and K500I mutations enhance the ability of Cas9 to recognize targets with NAG 
flanking PAMs. 
directed evolution assay. S. pyogenes cas9 was mutagenized by error-prone 
PCR and library amplicons were cloned into a plasmid carrying a spacer 
matching a TAG- adjacent target sequence on the fNM4g4 phage. Library cells 
were infected with lytic phage to screen for mutants displaying improved NAG 
cleaving efficiency. (b) Phage propagation was measured as the number of 
plaque-forming units (PFUs) per milliliter of stock on cells targeting the NAG-
adjacent proto- spacer and harboring plasmids with different mutations on cas9: 
one of the ‘‘evolved’’ alleles or each of the six mutations present in this allele. 
Mutations with PFU values significantly different than wild- type are highlighted 
(**p < 0.05 compared to WTCas9). Data are represented as mean ± SD of three 
representative biological replicates. (c) Colony-forming units (CFUs) obtained 
after phage infection of naive cells (not programmed to target any viral sequence) 
harboring plasmids with different mutations in cas9. Mutations with CFU values 
significantly different than wild-type are highlighted. Data are represented as 
mean ± SD of three representative biological replicates. (d) Location of residues 
I473 and K500 on the Cas9:single-guide RNA ribonucleoprotein (PDB: 4UN3). 
Red, I473; purple, K500; orange, sgRNA; green, target DNA (the GG PAM 
highlighted in red); gray, a-helical (REC) lobe; yellow, HNH domain; light blue, 
RuvC domain; blue, PAM-interacting CTD. 
Figure 3-1. Directed Evolution of cas9 Generates Mutants with 




Figure 3-2. Protection of host cells by hCas9 programmed against 
different NAG-flanked targets.  (a) The ability of hCas9 to target 
protospacers with different PAM was tested by measuring phage propagation in 
cells harboring CRISPR-Cas systems containing either wtCas9 or hCas9 and 
programmed to target the sequences shown, which are followed by TAG, AAG, 
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GAG or CAG PAMs. (b) Phage propagation was measured as the number of 
plaque forming units (pfu) per ml of stock, on cells targeting the TAG, AAG, GAG, 
and CAG-adjacent protospacers and hCas9. Data are represented as mean ± SD 
of three representative biological replicates. (c) Measurement of pfu formation on 
staphylococci carrying plasmids with different cas9 mutations after infection with 
φ85, a phage lacking the target recognized in φNM4γ4. Data are represented as 
mean ± SD of three representative biological replicates.  (d) Location of residue 
K500 on the Cas9:single-guide RNA ribonucleoprotein (PDB 4UN3). Purple, 
K500; orange, sgRNA; green, target DNA (the GG PAM highlighted in red); grey, 
alpha-helical (REC) lobe; yellow, HNH domain; light blue, RuvC domain; blue, 
PAM-interacting CTD. 
Given the requirement of Cas9 for the immunization phase of the CRISPR-
Cas immune response, i.e. the generation of phage-resistant bacteria through the 
acquisition of viral sequences as spacers84,85, I wondered whether the evolved 
Cas9 as well as the individual mutants affected this process. To test this, I 
introduced the different alleles of cas9 into a plasmid also harboring the tracrRNA 
coding sequence, the S. pyogenes SF370 CRISPR array (containing six spacers, 
none of them matching the genome of ϕNM4γ4) and the type II-A genes involved 
exclusively in the acquisition of new spacers, cas1, cas2 and csn284,85. S. aureus 
cells containing the different plasmids were infected with ϕNM4γ4 and the 
number of survivors were enumerated as colony forming units (cfu) (Figure 3-1c). 
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Cells harboring a vector control provide the threshold for the number of non-
CRISPR phage resistant mutants. Only a small fraction of cells containing wild-
type Cas9 are able to acquire new spacers, about 2-fold over the threshold 
control. In contrast, the evolved cas9 allele containing all six mutations increased 
the number of CRISPR-surviving cells by about 60-fold. Analysis of single 
mutants revealed that this highly significant increase was provided almost 
exclusively by the I473F mutation (Figure 3-1c). Due to the sharp enhancement 
of the CRISPR-Cas immune response conferred by the I473F mutation I decided 
to name the Cas9I437F mutant “hyper-Cas9”, or hCas9. I473 is located close to 
the surface of Cas9, outside of the PAM-interacting domain, and it is part of a 
projection from the Helical III domain that interacts with the nexus of the guide 
RNA87 (Figure 3-1d). This position does not suggest an evident effect of the 
I473F mutation on Cas9 activity and therefore I decided to investigate the basis 
for its phenotype by performing a detailed comparison with the CRISPR-Cas 
immune response mediated by wild-type Cas9. 
3.3. Mutant Cas9 enhances CRISPR adaptive immunity by 100-fold 
To perform a more accurate comparison between wild-type (wtCas9) and 
hCas9, I counted the number of CRISPR-mediated, phage resistant cells that 
arise after phage infection. Figure 3-3a shows representative plates of infected 
cells containing plasmids with the wtCas9 or hCas9 S. pyogenes CRISPR-Cas 
locus, showing a striking difference in the number of surviving colonies. As 
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mentioned before, most of these colonies arise from single cells that were able to 
acquire a new spacer matching the ϕNM4γ4 genome. However, a fraction of the 
surviving cells repels phage attack by non-CRISPR related mechanisms, such as 
envelope resistance84. To make a more accurate quantification of the CRISPR-
Cas response, I analyzed individual colonies by PCR of the CRISPR array28,84  to 
detect those in which new spacers were acquired, i.e. “adapted” cells (Figure 3-
3b). Not only did many more resistant colonies originated from cells harboring 
hCas9 (an average of 31 cfu for wtCas9 vs 4,312 cfu for hCas9, Figure 3-3c), but 
also most of them showed CRISPR-mediated phage resistance (23% for wtCas9 
vs 90% for hCas9, Figure 3-3c). 
We wondered whether this was a consequence of the specific substitution 
of I473 by phenylalanine. To test this, I introduced an I473A mutation into Cas9 
and compared this mutant with wtCas9 and hCas9 in this assay (Figure 3-4). I 
found that cells harboring the I473A mutant produced a number of CRISPR-
mediated immune cfu comparable to cells carrying wtCas9, but 10 times lower 
than the cfu obtained from infection of cells expressing hCas9. Therefore, I 
conclude that the I473F mutation increases the CRISPR-adaptive immune 
response through a specific effect of the phenylalanine residue in position 473 
and by more than two orders of magnitude: on average, approximately 7 cfu 
(31×0.23) per experiment for infected wtCas9-containing cells, and approximately 
3,863 cfu (4,312×0.90) for infected hCas9-expressing bacteria. I sequenced PCR 
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Figure 3-3. Cas9I473F or hyper-Cas9 Mounts an Enhanced CRISPR
Adaptive Immune Response.  (a) Representative plates obtained after lytic 
infection of cells harboring the full CRISPR system of S. pyogenes with WTCas9 
or hyperCas9 (hCas9) showing the number of surviving colonies. (b) Agarose 
gel electrophoresis of PCR products of the amplification of the CRISPR of arrays 
of surviving cells to detect newly acquired spacers (asterisks). Molecular markers 
(in kilobases) are indicated in black and the number of new spacers added in 
green. (c) Quantification of total surviving colonies (gray bars) and surviving 
colonies with newly incorporated spacers, as detected by PCR (blue and red 
bars). Data are represented as mean ± SD of three representative biological 
replicates. (d) Growth curves of cultures of cells harboring the full CRISPR 
system of S. pyogenes with WTCas9 or hCas9 with (+) or without (-) phage 
infection. (e) PCR-based analysis of the liquid cultures shown in (c) (at 24 hr 
post-infection) to check for the acquisition of new spacer sequences in the 
presence (+) or the absence (-) of phage infection by cells expressing WTCas9 
or hCas9. Molecular markers (in kilobases) are indicated in black and the number 
of new spacers added in green. Image is representative of three technical 
replicates.  
56	
products to determine the PAM of the spacers acquired by 40 colonies 
expressing wtCas9 or hCas9. Interestingly, all 40 spacers acquired by cells 
expressing hCas9 matched targets with an NGG PAM, suggesting that this 
nuclease can still target sequences followed by the canonical PAM in addition to 
targets with NAG PAMs. 
Figure 3-4. CRISPR-Cas immune response of cells expressing 
Cas9I473A. Cultures harboring plasmids with tracrRNA, cas1, cas2 and csn2
genes, and either wild-type, I473F or I473A cas9 alleles, were infected with 
ΦNM4γ4 phage on top agar media and poured on plates. After 24 hours of 
incubation at 37 °C the CRISPR-surviving colonies were counted. Data are 
represented as mean ± SD of three representative biological replicates. 
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Similar results were observed when cells in culture carrying naïve wtCas9 
or hCas9 CRISPR-Cas systems were infected with phage. Upon addition of 
ϕNM4γ4, the cultures lyse, as the vast majority of cells do not undergo spacer 
acquisition (Figure 3-3). Nonetheless, hCas9 cultures were able to regrow much 
earlier (~14 hours post-infection) than wtCas9 cultures (~17 hours post-infection). 
PCR analysis of the population of surviving cells (i.e., using DNA extracted from 
the whole culture, not individual resistant bacteria) at 24 hours post-infection 
corroborated the earlier observation that hCas9 cells mount a more robust 
CRISPR immune response (Figure 3-3e). Whereas the PCR products using DNA 
from immune cells carrying wtCas9 showed the presence of both adapted and 
non-adapted CRISPR arrays in the surviving population, the PCR results from 
cultures carrying hCas9 showed very little non-adapted CRISPR arrays, with the 
great majority of the cells acquiring one or two new spacers. Altogether these 
data show that the I473F mutation in Cas9 allows for a more robust CRISPR-Cas 
immune response due to a specific effect of the phenylalanine residue. 
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3.3.1. Hyper Cas9 provides wild-type cleavage eff iciency  
The CRISPR-Cas response can be divided into two distinct stages7. First 
there is spacer acquisition, where sequences from the invading virus are 
incorporated into the CRISPR array. This is followed by the second stage where 
the acquired spacers provide the crRNA guides to the Cas nucleases for the 
destruction of the viral DNA. Therefore, the enhanced immunity phenotype of 
hCas9 documented in Figure 3-3 could be in principle due to an increase in the 
frequency of spacer acquisition, a more robust cleavage by hCas9 of its targets, 
or both. 
First, I considered the possibility that hCas9 could provide better cleavage 
of the infecting viral DNA. In this scenario both wtCas9 and hCas9 populations 
can acquire a similar number of new spacers but a more robust cleavage of the 
target DNA by hCas9 would lead to a faster recovery of the bacteria that acquired 
the spacers. This will result in the clonal expansion and the consequent increase 
in the number of surviving bacteria. To test this hypothesis, I infected cells 
carrying plasmids with either wtCas9 or hCas9 programmed to target the 
ϕNM4γ4 virus and the tracrRNA gene, but without the spacer acquisition 
machinery (cas1, cas2 and csn2). This genetic background supports CRISPR-
Cas anti-viral defense but does not allow the acquisition of new spacer 
sequences84. Because our data suggested that hCas9 can still target 
protospacers followed by NGG PAMs, I tested the immunity of cells programmed 
to attack targets with either an NAG or an NGG PAM located in the same region 
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of the ϕNM4γ4 genome (Figure 3-5). As a control, cells harboring a vector 
control were also infected. 
Figure 3-5. In vivo and in vitro targets. (a) Region of the ΦNM4γ4 phage 
genome (nucleotides 1441 to 1490) containing the TAG- and TGG-flanked 
protospacers, yellow and blue respectively, used in Figures 3-6a and 3-6b. (b) 
Sequences of the dsDNA target oligonucleotides used in Figure 3-6c. The 
protospacer sequence is the same, but it is flanked by either a TAG (yellow) or 
TGG (blue) PAM sequence. Radiolabel is at the 5’ end (P). Grey and black 
arrowheads mark the cleavage sites of the RuvC and HNH domains, 
respectively. 
Bacteria containing different plasmids were infected with phage during 
exponential growth and the optical density of the culture was followed over time 
to measure the immunity provided by Cas9 cleavage of the viral genome (Figure 
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3-6a). As expected, control cells were rapidly lysed by the addition of phage. In 
contrast, cells expressing wtCas9 programmed against an NGG target cleared 
the infection efficiently and continued the exponential growth. In contrast, the 
poor targeting of NAG-flanked protospacers by wtCas9 led to substantial lysis, 
although not as dramatic as the non-Cas9 control, suggesting a low level of 
target cleavage. The population of hCas9-containing cells targeting an NGG-
flanked viral protospacer was protected to levels indistinguishable from the 
immunity provided by bacteria expressing wtCas9 programmed against the same 
target. Targeting of the protospacer followed by an NAG PAM was more efficient 
in cells having hCas9 than in the wtCas9 population. However, hCas9 did not 
provide full immunity as was the case for NGG-containing targets. Similar results 
were obtained when phage propagation was measured instead of cell survival 
(Figure 3-6b). To do this, I compared the number of plaques (measured as 
plaque forming units or pfu) obtained when a ϕNM4γ4 lysate was applied to 
plates seeded with the five different cultures used in Figure 3-6a. Cells harboring 
an empty vector allowed extensive phage propagation, up to more than 1010 pfu 
per ml of phage stock. In contrast, bacteria harboring wtCas9 or hCas9 
programmed to target the NGG-flanked protospacer in the ϕNM4γ4 genome 
reduced phage proliferation by more than four orders of magnitude (~ 106 pfu/ml). 
When the target contained an NAG PAM, wtCas9 only reduced viral 
multiplication by an order of magnitude compared to the non-CRISPR control, 
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whereas hCas9 reduced it by about three orders of magnitude, but nevertheless 
failing to fully restrict the virus. 
Figure 3-6. hCas9 has increased interference eff iciency against 
NAG-adjacent, but Not NGG-adjacent, targets. (a)   Growth curves of 
cultures infected with fNM4g4 harboring the WTCas9 or hCas9 (but not Cas1, 
Cas2, and Csn2) programmed to target either NAG- or NGG-flanked viral 
sequences. (b) Phage propagation, measured in PFU/mL, of the bacteria 
presented in (a). Data are represented as mean ± SD of three representative 
biological replicates. (c) Cleavage of radiolabeled dsDNA targets, flanked by 
either NGG or NAG PAMs, by WTCas9 or hCas9.  (d) Quantification of the 
cleavage results shown in (c). Data are represented as mean ± SD of three 
representative biological replicates. 
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Both in vivo experiments measuring bacterial survival (Figure 3-6a) and 
phage propagation (Figure 3-6b) suggest that hCas9 has not improved efficiency 
of cleavage of NGG-flanked targets and displays only a small increase in the 
cleavage of NAG-flanked sequences. To unequivocally demonstrate this, I 
performed in vitro cleavage assays with purified wtCas9 and hCas9 (Figure 3-
6c). In this case,  I was able to compare cleavage of radiolabeled 
oligonucleotides containing the same protospacer sequence followed by either a 
TGG or TAG PAM (Figure 3-5b). Consistent with in vivo data, experiments 
showed similar cutting rates of the NGG target for wtCas9 and hCas9. 
Quantification of the cleavage products showed that hCas9 cleaved more of the 
NAG target than wtCas9 over longer timescales (Figure 3-6d). Altogether, the 
data presented in Figure 3 indicate that while there is a modest increase in the 
NAG-targeting properties of hCas9, this cannot explain the rise in the number of 
CRISPR-resistant colonies mediated by the I473F mutation (Figure 3-3c). 
3.3.2. Hyper Cas9 promotes higher rates of spacer acquisit ion 
A second hypothesis that could explain the increase in CRISPR-Cas 
immunity conferred by hCas9 is, as explained above, a possible increase in the 
frequency of spacer acquisition by the cells expressing this mutant. To test this, I 
performed a comparison of the spacer repertoires acquired by cells harboring 
wtCas9 or hCas9. I made two plasmid libraries, carrying the spacer acquisition 
genes cas1, cas2 and csn2 and wtcas9 or hcas9, the tracrRNA gene and the S. 
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pyogenes array of repeats and spacers preceded by a “barcode” sequence of 10 
nucleotides 50 bp immediately upstream of the CRISPR array (Figure 3-7a). 
Cells harboring each library were infected with phage ϕNM4γ4 and DNA from the 
adapted cells was used to amplify the CRISPR array via PCR and collect 
sequence information of all the new acquired spacers using next generation 
sequencing. The primers used also amplify the barcode sequence (Figure 3-7a) 
and therefore each new spacer sequence can be associated with a unique 
barcode, allowing us to count how many times a given spacer was independently 
acquired in each bacterial population. Over three million reads belonging to either 
library were analyzed. 
The frequency of reads corresponding to each acquired spacer sequence 
was plotted according to its position in the ϕNM4γ4 genome (Figure 3-8a). 
Analysis of the PAMs of the acquired spacers showed that over 99.5% of the 
spacer reads contained the NGG sequence in both libraries (Figure 3-8b), 
corroborating our in vivo data showing that hCas9 retained NGG PAM specificity. 
In addition, I looked at the repertoire of unique different spacers independently of 
the number of reads per sequence (Figure 3-8c). Consistent with our previous 
finding that the PAM specificity of Cas9 is responsible for the PAM sequence of 
the new protospacers, the hCas9 library showed a 5-fold increase in the 
acquisition of spacers matching NAG-flanked targets. I also observed an 
increase in the total number of different spacer sequences, from 1980 for wtCas9 
cells to 2500 for the hCas9 sample. 
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Figure 3-7. hCas9 Promotes Higher Rates of Spacer Acquisit ion  . (a) 
Schematic diagram of the S. pyogenes CRISPR locus showing the barcode and 
primers (arrows) used to measure the number of independent spacer acquisition 
events. (b) Cultures expressing WTCas9 or hCas9 were infected with fNM4g4 
phage, and surviving cells were collected after 24 hr, had DNA extracted, and 
were used as template for PCR of the CRISPR arrays. Amplification products 
were separated by agarose gel electrophoresis (not shown), and the DNA of the 
expanded CRISPR array was subject to MiSeq next-generation sequencing. The 
number of barcodes for each spacer sequence across the phage genome, 
normalized by the total number of spacer reads obtained, was plotted. (c) The 
hCas9/WTCas9 frequency of independent acquisition events ratio for 1,938 
common spacer sequences was plotted across the phage genome. The zone 
where the ratio is greater than one is shown in gray. The red line shows the 
average ratio. (d) Same as (b) but without phage infection; i.e., a measure of 
acquisition of spacers derived from the host chromosome and resident plasmids. 
(e) Pairwise competition between staphylococci expressing WTCas9 or hCas9. 
The change in the relative frequency of cells carrying the hcas9 allele (y axis) is 
plotted against the number of culture transfers (1 transfer/day, x axis). 
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To calculate the frequency of acquisition of every spacer I divided the 
number of different barcodes for a given spacer sequence by the total number of 
reads. This value was plotted according to its position in the ϕNM4γ4 genome 
(Figure 3-7b). The data show an increase in the frequency of acquisition in 
hCas9 cells, with a 6-fold increase in the average frequency. For all spacer 
sequences shared between the two libraries (1938 sequences were shared 
between the 1980 and 2500 different sequences for wtCas9 and hCas9, 
respectively), I calculated the ratio of unique adaptation events (i.e. number of 
different barcodes) for hCas9 reads compared to wtCas9 (Figure 3-7c). I found 
that more than 97% of the spacers were acquired more frequently in the hCas9 
library (ratio > 1), with an average ratio of ~18. All together, these findings show 
that hCas9 provides the host bacterium with more efficient spacer acquisition and 
suggest that this is a major contribution to the enhanced CRISPR-Cas immunity 
granted by hCas9. 
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Figure 3-8. Analysis of next-generation sequencing results. (a) Data 
presented in Figure 3-7b was plotted as the number of reads for each spacer 
sequence across the phage genome, normalized by the total number of spacer 
reads obtained. Spacers matching protospacers with NGG PAMs are shown in 
blue, with NAG PAMs in yellow. (b) Quantification of the data shown in panel 
a.  (c) Quantification of the data shown in Figure 3-7b.  (d) Alignment of Cas9
protein sequences belonging to type II CRISPR-Cas systems. Highlighted in 
orange is the I473 residue. An equivalent residue is not found in some type II-B 
and II-C systems.  (e) Fraction (%) of staphylococci retaining the plasmid 
harboring wtcas9 and hcas9 after 10 days of culture; with one transfer (1:100 
dilution into fresh media) per day. Cells were plated in solid media with and 
without chloramphenicol, an antibiotic that selects for cells harboring the 
pCRISPR plasmid. The fraction of staphylococci carrying this plasmid was 
obtained dividing the chloramphenicol-resistant cfu by the total cfu count. Data 




Here I performed random mutagenesis on the cas9 gene to identify 
mutants with an expanded CRISPR-Cas response. Specifically, I looked for 
mutants that would allow Cas9 to recognize not only NGG- but also NAG-
containing targets. I isolated a mutant, harboring an I473F substitution, that 
displayed a modest increase in NAG-target recognition. More importantly, the 
mutation increased the CRISPR-Cas immune response of the bacterial host by 
more than two orders of magnitude, as measured by the number of CRISPR-
mediated bacteriophage resistant colonies obtained after phage infection. Due to 
this hyper-activity in CRISPR immunity I named the mutant version of Cas9 
hyper-Cas9, or hCas9. Deeper analysis of hCas9 revealed that it can perform 
crRNA-guided cleavage of targets containing an NAG PAM better than wtCas9. 
However, this improvement is minor and does not seem to contribute significantly 
to the rise of a high number of CRISPR-mediated resistant cells. On the other 
hand, upon phage infection bacteria expressing hCas9 are able to acquire many 
more viral spacers than those expressing wtCas9. I hypothesize that this high 
rate of spacer incorporation is the basis for the observed increase in the 
CRISPR-mediated phage resistant colonies. 
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At the molecular level, the mechanism by which the I473F mutation 
enables this increase in spacer acquisition is not clear. I previously reported the 
existence of a complex between the four Cas proteins encoded by the type II-A 
CRISPR locus, namely Cas9, Cas1, Cas2 and Csn284. I hypothesized that these 
complex functions in spacer acquisition, with Cas9 selecting sequences flanked 
by NGG PAMs84 and Cas1 and Cas270,79 being involved in the integration of 
these sequences into the CRISPR array. The precise role of Csn2 in spacer 
acquisition remains to be elucidated. I thought that the I473F mutation could 
affect the formation of the complex, since the mutated residue is located on Cas9 
surface and could participate in its interaction with another Cas protein. The 
substitution could enhance protein-protein interactions and either increase the 
abundance or the stability of the complex, thus increasing the rate of spacer 
acquisition. To test this, I incubated the four proteins along with a single-guide 
RNA34 and subjected them to gel filtration to detect the formation of the complex. 
However, I did not observe significant amounts of stable complexes neither in the 
presence of wtCas9 nor hCas9. In wtCas9, the isoleucine residue is in direct 
contact with bases of the tracrRNA (Figure 3-1d) that are equivalent to the nexus 
in the single-guide RNA88. Specifically, nucleotide U59 of the tracrRNA inserts 
into a hydrophobic pocket lined by I473 and its adjacent residues87. It is possible 
that the bulkier phenylalanine residue could interfere with the tracrRNA:Cas9 
association, affecting the involvement of Cas9 in the immunization step of the 
CRISPR-Cas response. This hypothesis is supported by the wild-type phenotype 
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of the I473A mutation (Figure 3-4), since the smaller alanine residue most likely 
will not interfere with the tracrRNA interaction. Another mutation in a residue 
close to I473, K500I, also seems to affect Cas9 target specificity, but not the rate 
of spacer acquisition. Future work will explore the importance of this region in 
Cas9 activity during the different phases of CRISPR-Cas immunity. 
In a recent study89, the E. coli type I-E CRISPR-Cas adaptation machinery 
has been repurposed as a recording device to store information (such as 
environmental signals) in the form of spacers in the CRISPR array. Because the 
adaptation frequency is relatively low, decoding requires deep sequencing of a 
population of cells. This limits the number of stimuli that can be recorded. Using 
hyperactive adaptation machinery such as hCas9 can boost the adaptation 
frequency and thus the recording capacity of such synthetic devices. Moreover, 
combined with introduction of sheared genomic DNA, the hyperactive CRISPR 
adaptation machinery can be used to generate diverse and unbiased gRNA 
libraries in vivo. I speculate that hCas9 is able to sample much larger genomes 
then the type I-E Cas1-Cas2 complex 
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Chapter IV. 
Spacer Acquisit ion and Immunological 
Diversity 
Previous studies have shown that the abundance of each spacer in the 
surviving population is highly uneven. However, the molecular mechanisms 
underlying this bias are poorly understood. Here, I studied the factors that affect 
the distribution of individual spacer sequences after phage infection of cells 
harboring the type II-A CRISPR system from Streptococcus pyogenes. I show 
that spacer patterns are established early during infection and correlate with 
spacer acquisition rates, but not with spacer targeting efficiency. I also show that 
the rate of spacer acquisition depends on unique sequence elements within the 
spacer, which in turn determines the abundance of different spacers within the 
adapted population. Our results elucidate a fundamental mechanism behind the 
generation of immunological diversity during the type II CRISPR-Cas response. 
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4.1. An uneven spacer distribution across the phage genome 
In the type II-A CRISPR system from Streptococcus pyogenes, cleavage is 
performed by the crRNA-guided nuclease Cas934, whose catalytic activity 
depends on the recognition of a 5’-NGG-3’ protospacer adjacent motif (PAM)33,34 
Cas9 contains a PAM-interacting domain to recognize this motif33,71 that is not 
only required for target cleavage but also for the acquisition of spacers with the 
appropriate PAM84. 
Besides the presence of a functional PAM, the rules that govern spacer 
acquisition in type II CRISPR-Cas systems are not completely understood. 
Multiple studies have shown an uneven pattern of spacer acquisition, where 
different spacer sequences have markedly different abundances within the 
population of cells that survive phage infection40,84,90. This observation led to the 
hypothesis that some spacers become overrepresented because they are more 
effective at directing targeting and/or cleavage by Cas9 and therefore have a 
selective advantage40. However, even when spacer acquisition was measured 
within 30 minutes of infection, i.e. before the viral lytic cycle is completed and the 
spacers cannot be selected for their abilities to guide DNA destruction, the 
pattern of spacer acquisition is constricted to the viral region that is first injected 
but with highly variable frequencies of acquisition for different spacers sequences 
within this genomic location91. These data suggest that the abundance of a 
spacer in the population of surviving bacteria can be independent of its targeting 
properties and determined solely by its acquisition rate. 
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Here I used the type II-A CRISPR system from Streptococcus pyogenes 
expressed in Staphylococcus aureus RN4220 cells84 to investigate the 
mechanisms behind the pattern of spacer acquisition when cells are infected with 
the staphylococcal phage ϕNM4γ464,84. First, I determined that this pattern is 
remarkably reproducible, with a set of spacer sequences consistently acquired 
at high frequencies. By measuring spacer abundance early and late during 
infection, I show that the frequency of individual spacers is mainly determined 
at the onset of infection and that there is little selection of spacer sequences 
thereafter. This led to the hypothesis that spacer abundance depends on the 
rate of acquisition rather than enhanced Cas9 cleavage activity. I tested this on 
selected spacer sequences at each end of the distribution spectrum by 
performing targeting assays and quantifying CRISPR acquisition of spacer-
length oligonucleotides. These experiments demonstrated that high and low 
abundance spacers have similar targeting abilities but differ dramatically in 
their efficiency of acquisition. I established that the intrinsic spacer sequence 
dictates its acquisition rate, with the sequences proximal to the PAM being 
most critical. Our studies reveal that, for type II-A systems, spacer acquisition 
rates are fundamental to determine the distribution and diversity of the 
CRISPR-Cas immune response. 
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4.2. Spacer distribution is biased and reproducible 
To analyze spacer distribution in the type II-A CRISPR system of S. 
pyogenes (Figure 4-1a) I performed infection assays with lytic phage ϕNM4γ4, 
as described previously92. DNA from surviving cells was used to amplify the 
CRISPR array by PCR and perform next generation sequencing of newly 
acquired spacers. I performed the infection in duplicate and obtained two libraries 
of 2.52 and 2.28 million phage-mapping reads, respectively. Of all the possible 
2,318 NGG-adjacent protospacers on the genome of ϕNM4γ4, 2,096 were 
sampled in both libraries. The frequency of each spacer was normalized as 
reads per million (RPM) and plotted across the phage genome (1 kb bins, Figure 
4-1b). I observed a similar pattern of spacer distribution for each duplicate 
experiment. To determine if the correlation is present not only in the groups of 
spacers within each 1 kb bin, but also at the level of the individual spacer 
sequences, I compared the RPM value for each of the 2,096 spacers (Figure 4-
1c). 
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Figure 4-1. Acquired spacer sequences display a consistent 
distribution pattern. (a) Schematic diagram of the type II-A CRISPR system 
from Streptococcus pyogenes. Arrows indicate the position of the PCR primers 
used to check for spacer integration. (b) Average abundance (in reads per 
million per 1-kb bins, RPM) of φNM4γ4 viral sequences incorporated as spacers 
into the CRISPR array, mapped against location on the phage genome, in 
duplicate (red and green traces). (c) Individual spacers common to the two data 
sets in (b) were plotted with RPM values for replicate 1 on the x axis and 
replicate 2 on the y axis. The dotted line represents the linear regression fit. Ten 
spacers were color-coded based on their abundance (warm colors for low 
abundance and cold colors for high abundance). 
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We found a remarkable correlation of the spacer frequencies in both 
replicas, particularly of the most abundant spacer sequences. I arbitrarily picked 
five spacer sequences with high or low RPM and marked them with different 
colors to follow their abundance over different experiments. This is an effort to 
illustrate the relative consistency in the distribution of individual spacer 
sequences, for example after mapping the spacers across the phage genome in 
our replicates (Figure 4-2a-c). To test if this correlation extends to experiments 
using other phages and type IIA CRISPR-Cas systems, I performed duplicate 
infection experiments of cells containing the S. pyogenes type IIA system with the 
phage ϕ8593 (Figure 4-2d), or cells harboring the type IIA (also known as 
CRISPR317) from Streptococcus thermophilus with ϕNM4γ4 (Figure 4-2e). 
Although I obtained fewer spacer reads in both cases (the efficiency of spacer 
acquisition is reduced under these conditions84), a very strong correlation for 
spacer abundance in the replicas was found. Altogether, these results indicate 
that the abundance of individual spacer sequences within the population of 
surviving cells is relatively constant during the type IIA CRISPR-Cas immune 
response. 
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Figure 4-2. Biased sampling of phage DNA protospacers is a feature 
of other bacteriophages and type II CRISPR systems. (a), (b) 
Abundance (in reads per million, RPM) of φNM4γ4 viral sequences incorporated 
as spacers into the CRISPR array, mapped against location on the phage 
genome, in duplicate (raw data for Figure 4-1b and 4-1c). (c) Overlap of data in 
(a) and (b), zoomed on the first 5kb of the viral genome. Only spacers with RPM 
> 5,000 are shown (d). RPM values of spacers sampled in two replicates during 
infection with lytic phage φ85 of cells harboring the Streptococcus pyogenes 
CRISPR system. (e) RPM values of spacers sampled in two replicates during 
infection with φNM4γ4 of cells harboring the Streptococcus thermophilus type II-
A CRISPR3 system. 
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4.2.1. Effects of DNA cleavage eff iciency on spacer distribution 
In principle, the different but reproducible abundance of spacers could be 
explained by two mutually non-exclusive forces that depend on their individual 
sequences: their inherent frequency of acquisition and/or their efficiency of viral 
targeting. To explore these possibilities, I compared the spacer distribution 30 
minutes after infection, when the great majority of cells have not lysed yet (the 
ϕNM4γ4 viral cycle takes ~ 40 minutes), with the distribution obtained after 16 
hours of infection, a time during which the acquired spacers can be selected 
against or for their targeting properties (Figure 4-3a). 
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Figure 4-3. Spacer distribution due to init ial acquisit ion is not 
perturbed over the course of a l ive phage infection. (a) Diagram of 
assay used to measure the effects of interference efficiency on spacer 
abundance. (b) Average abundance (in reads per million per 1-kb bins, RPM) of 
φNM4γ4 viral sequences incorporated as spacers into the CRISPR array, 
mapped against location on the phage genome, in the early and late time point 
libraries (red and green traces). (c), (d) Abundance (in reads per million, RPM) 
of φNM4γ4 viral sequences incorporated as spacers into the CRISPR array, 
mapped against location on the phage genome in the early and late time point 
libraries (raw data for Figure 4-4). (e) Spacers ranked by decreasing fitness 
(ratio of abundance in late time point divided by abundance in early time point) 
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were order of magnitudes more frequent than other spacers with similar finesses 
(Figure 4-4b). Interestingly, I did not detect a strong positive selection for any 
spacer sequence (the maximum fitness value was 3.3), but there were 14 that 
displayed more than a 100-fold negative selection (Figure 4-4c, Figure 4-3e). On 
average, the acquired spacers have a fitness value close to 1 (Figure 4-4c), with 
approximately half of them displaying fitness higher than 1 and half lower than 1 
(Figure 4-3e). These findings indicate that the relative abundance of spacer 
sequences is determined at their time of acquisition, early during the CRISPR-
Cas immune response, and remains relatively constant during the targeting 
phase of CRISPR immunity. 
We analyzed over 0.72 million spacers for the early time point and 12.3 
million spacers for the late time point, with 1,517 sequences shared between the 
two libraries. I observed a strong correlation for the values obtained at both time 
points for the frequency of each individual spacer (Figure 4-4a) and for their 
overall distribution across the phage genome (Figure 4-3b-d). This result 
suggests that spacer abundance is determined early after infection, and selection 
throughout the recovery of CRISPR-adapted cells has a minimal impact on 
shaping the spacer distribution. To explore this more directly, I calculated the 
fold-increase in abundance from the early time point to the late time point for 
each spacer. This value reflects the fitness of each sequence after its acquisition; 
i.e., the positive or negative selection suffered by a spacer due to its targeting
abilities. I found that the fitness range of the entire spacer repertoire was narrow 
and did not correlate with spacer abundance (Figure 4-4b). For example, our set 
of highly abundant spacers had average finesses close to 1, even though they 
Figure 4-4. The spacer distribution pattern is established early 
during infection. (a) Individual spacers common to the early and late time 
point samples plotted as RPM values against each other. (b) Spacer abundance 
in the live-phage sample (Figure 4-1) as a function of interference efficiency 
(fitness = abundance in late / early time point). (c) The fold increase in 
abundance in the late vs. early sample (fitness, y-axis) mapped across the phage 




along with barcoded leaders were amplified by PCR (Figure 4-5a) and subjected 
to next-generation sequencing. I analyzed 2.00 million spacer reads each with its 
respective barcode that sampled almost all (2,274) of the existing protospacers 
on the ϕNM4γ4 genome (Figure 4-6a-b). To test the barcoded system, I plotted 
the relative abundance versus the number of different barcodes for each 
individual sequence (Figure 4-6c). Assuming that different barcode sequences 
in front of the same spacer are the result of independent events of integration, 
this value reflects how many times a given spacer was acquired during 
4.2.2. Effects of acquisit ion rates on spacer distribution 
To test whether targeting efficiency affects the relative abundance of 
individual spacer sequences, I performed a barcoded, phage-free spacer 
acquisition experiment. For this I used a plasmid-based, modified type IIA 
CRISPR-Cas system (Figure 4-5a) in which a single-repeat CRISPR array was 
preceded by a random 10 nt sequence located 50 bp immediately upstream of 
the repeat, a barcoding strategy I previously used to count independent 
acquisition events92. In addition, expression of the cas1, cas2 and csn2 genes, 
essential for spacer acquisition, is controlled by an anhydrotetracycline-inducible 
promoter, allowing to turn on and off spacer integration84,91. Instead of using a 
live lytic virus, cells harboring this engineered CRISPR-Cas locus were 
transformed via electroporation with ϕNM4γ4 phage DNA, sheared into ~150 bp 
fragments by sonication, in the presence of anhydrotetracycline. After two hours 
the inducer was washed off, DNA was extracted from cells and the CRISPR loci 
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Figure 4-5. Spacer abundance is determined by the rate of 
acquisit ion. (a) Schematic diagram of the modified S. pyogenes CRISPR locus 
showing the location of the leader barcodes and primers (arrows) used to 
quantify the number of independent spacer acquisition events from sheared 
phage DNA. (b) Overlap of spacer distribution during a live phage infection 
(Figure 4-1) and number of barcodes as a measure of acquisition frequency, both 
plotted in 1-kb bins. (c) Comparison between abundance of individual spacers 
during a live phage infection and independent acquisition events from sheared 
phage DNA. 
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We then compared the number of barcodes with the number of reads 
obtained for each spacer sequence in the experiment using live phage 
presented Figure 1. In this way I can determine how much of the spacer 
distribution obtained after viral infection (measured as the average RPM of the 
replica experiments of Figure 4-1) can be explained by the intrinsic rate of 
acquisition of each viral spacer sequence (measured by the number of 
barcodes obtained in Figure 4-6). First I compared the distribution patterns 
across the ϕNM4γ4 genome (Fig. 4-5b). I found very similar distribution 
patterns, with a conservation of most peaks and valleys in both curves (note 
that the RPM and number of barcode values are intrinsically different and 
therefore the curves do not overlap). Next, I plotted both values against each 
other and found a good correlation, in which our ten selected spacers 
maintained their low or high abundance, and with an r2 value of 0.536 (Fig. 4-
5c). This indicates that the distribution of at least half of the spacers acquired 
in response to viral infection can be explained by their intrinsic rate of 
acquisition; i.e. independent of the targeting abilities of the spacer sequence. 
infection. I detected a strong correlation between the abundance of a spacer 
and its number of barcodes, a result that validates the use of barcode count as 
an absolute measure of the acquisition of a given spacer sequence present in 
the ϕNM4γ4 genome. 
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Figure 4-6. Oversampling of phage protospacers is due higher rates 
of acquisit ion. (a) (b) Abundance (in reads per million, RPM) of spacers 
incorporated into the CRISPR array, mapped against location on the phage 
genome, following electroporation of sheared phage DNA (raw data for Figure 4-
5). (c) Abundance of individual spacers following electroporation of sonicated 
phage DNA plotted against barcodes as a measure of the number of times each 
spacer was acquired. 
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4.3. Analysis of spacer sequences that determine the rate of 
acquisit ion 
Our data suggests that the efficiency of the spacer acquisition process, i.e. 
the selection and integration of a PAM-flanked phage sequence that happens 
early during infection, is the most important factor to determine the abundance of 
a spacer sequence during the CRISPR-Cas immune response. If this hypothesis 
is correct, when comparing a high- and low-abundance spacer it would be 
expected that (i) their ability to direct Cas9-mediated DNA cleavage should be 
similar, and (ii) their rate of acquisition should be dramatically different. To test 
these predictions, I selected two spacer sequences that were consistently over- 
and under-represented (the “dark green” and “red” spacers, respectively, in 
Figure 4-1c) in all our assays (Fig. 4-7a). 
We tested the first prediction by comparing the efficiency of in vitro DNA 
cleavage by Cas9 using each of these spacers as guides and I found similar 
cleavage kinetics (Fig. 4-7b and Figure 4-8a-c). Second, I measured the cleaving 
capacity of each of these spacers in vivo, through the quantification of the 
reduction in phage propagation that they mediate (Fig. 4-7c). I did not detect 
significant differences between the spacers, a result that demonstrates that not 
only in vitro, but also in vivo, these sequences provide similar levels of defense. 
Because the sequences I decided to follow in these assays reside in different 
regions of the phage genome, which could be a variable affecting their targeting 
ability91, I repeated these assays with two other sequences that overlap with 
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each other but have markedly dissimilar abundances (“light blue” and “tan” in 
Figure 4-1c, Figure 4-9a). Again, I found no differences in DNA cleavage in vitro 
(Figures 4-8a,d,e and 4-9b) or in vivo (Fig. 4-9c). All these results corroborate the 
prediction that DNA targeting does not dictate spacer abundance. 
Figure 4-7. High and low abundance spacers have similar 
interference eff iciencies. (a) Sequences of a high abundance (Figure 4-1, 
dark green) and low abundance (Figure 4-1, red) spacer, following infection of 
CRISPR cells with live phage. (b) Quantification of in vitro cleavage of a 2-kb 
phage target by various concentrations of Cas9 loaded with sgRNAs 
corresponding to the two spacers in (a). (c) Phage propagation measured as the 
number of plaque forming units (pfu) per ml of stock, on cells without CRISPR or 
cells loaded with Cas9 and a spacer targeting either one of the phage 
protospacers in (a). 
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Figure 4-8. High and low abundance spacers have similar 
interference eff iciencies. (a) Location on the phage genome of the spacers 
colored dark green, red, light blue and tan in Figure 4-1. (b) Agarose gels in 
triplicate of in vitro cleavage products of 2-kb phage targets by various 
concentrations of Cas9 loaded with sgRNAs corresponding to the four spacers in 
(a). The tested Cas9 concentrations were 6.26, 12.5, 25, 50 and 100nM. 
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Figure 4-9. Partial ly overlapping spacers can provide similar 
interference eff iciencies, in spite of highly dissimilar abundances. 
(a) Sequence of two high abundance (Figure 4-1, light blue) and low abundance 
(Figure 4-1, tan) overlapping spacers. (b) Quantification of in vitro cleavage of a 
2-kb phage target by various concentrations of Cas9 loaded with sgRNAs 
corresponding to the two spacers in (a). (c) Phage propagation measured as the 
number of plaque forming units (pfu) per ml of stock, on cells without CRISPR or 
cells loaded with Cas9 and a spacer targeting either one of the phage 
protospacers in (a). (d) Relative acquisition rates (%) following electroporation of 
a single dsDNA oligonucleotide containing both protospacers. 
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To test the second prediction, that super-spacers have an intrinsic higher 
rate of acquisition, I designed an assay to compare the relative frequency of 
CRISPR incorporation of different sequences. I co-transformed staphylococci 
carrying the engineered type IIA CRISPR-Cas locus used for the acquisition of 
spacers from sheared phage DNA with annealed, dsDNA oligonucleotides at 
equimolar concentrations. Transformation was followed by next-generation 
sequencing of the amplified CRISPR array to quantify the relative frequency of 
acquisition for each transformed oligonucleotide. First, I compared the acquisition 
of the selected over- and under-represented sequence (“dark green” and “red” 
sequences, respectively, in Figure 4-1c), using oligonucleotides containing only 
the 30-nt spacer sequence followed by the 3-nt PAM (Figure 4-7a). I observed a 
striking difference in the number of reads, with ~ 96 % of the reads from oligo-
derived spacers matching the highly abundant sequence (Fig. 4-10a). 
Figure 4-10. Spacer sequences affect their rate of acquisit ion. 
Relative acquisition rates (%) of spacers following electroporation of various pairs 
(a)(c) or a set of 10 (c) dsDNA oligonucleotides mixed equimolar ratios. 
To corroborate this finding, I performed spacer-specific PCR after transformation 
using each of the spacer sequences as reverse primers to amplify the CRISPR 
array. Consistent with our next generation sequencing data, I was able to detect 
a strong PCR product only when using the highly acquired spacer as reverse 
primer (Fig. 4-11a). I repeated these assays using extended oligonucleotides 
harboring additional (15-nt) phage sequences flanking the spacers and obtained 
similar results (Figure 4-11a-c). In addition, I compared the frequency of 
acquisition of another high- and low-abundance spacer pair (the “light green” and 
“orange” spacers in Figure 1c, respectively), and observed the same differential 
integration into the CRISPR array (Fig. 4-10a). Finally, I measured acquisition of 
the two overlapping spacers with dramatically different abundances (Figure 4-9a) 
and found that even when a single dsDNA oligonucleotide containing both 
sequences is used, mostly the abundant spacer sequence is acquired (Figure 4-
9d). Altogether, these experiments demonstrate that for a given spacer 
sequence, its efficiency of acquisition but not its targeting capabilities, correlate 




Figure 4-11. Sequence determinants within the protospacer 
sequence affect the rate of acquisit ion. (a) Qualitative PCR to assess the 
integration of a low abundance (Figure 4-1, red) and high abundance (Figure 4-1, 
dark green) spacer after electroporation of corresponding dsDNA 
oligonucleotides mixed in a 1:1 molar ratio. The oligonucleotides tested were 
33bp long (protospacer + PAM only) or 63bp long (15bp upstream + protospacer 
+ PAM + 15bp downstream). Reverse primers anneal on the integrated spacers. 
(b) Sequence of oligonucleotides containing the protospacers in (a) with 15bp 
upstream and downstream of the protospacer swapped or not. (c) Relative 
acquisition rates (%) of spacers in (b) following electroporation of pairs of dsDNA 
oligonucleotides mixed equimolar ratios. (d) Unweighted probability Logo of the 
top 1% protospacers generated using kpLogo (showing only 10bp upstream of 
the PAM). Nucleotides shown on top were enriched, while the ones shown on the 
bottom were depleted in the spacers used to create the logo. Enriched or 
depleted consensus sequences are shown to the right.
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The above results suggest that there must be some element in the 
sequence of super-spacers that increases their rate of acquisition. To test this, I 
divided the sequence of the spacers into PAM-distal, middle and PAM-proximal 
10-nt regions (Figure 4-10a) and swapped these regions in the super-spacer and 
low abundance spacer sequences. Electroporation with different pairs of 
swapped oligos, followed by next generation sequencing of expanded CRISPR 
arrays revealed that the presence of the 10-nt PAM-proximal region of the super-
spacer was necessary and sufficient to ensure high levels of acquisition of a 
dsDNA oligo (Figure 4-10a). Moreover, the addition of the 10-nt PAM-proximal 
region of the “dark green” highly acquired spacer, but not the middle or PAM-
distal sequences, was also sufficient to increase the frequency of acquisition of 
the “orange” low-abundance spacer (Figure 4-10a). To corroborate these 
findings, I co-transformed 10 different dsDNA oligonucleotides containing 
different combinations of 10-nt regions of the “dark green” and “red” spacer 
sequences (Figure 4-10b). Again, I found that dsDNA oligos containing the 10-nt 
PAM-proximal sequence of the highly acquired spacer were integrated into the 
CRISPR array at significantly higher frequencies than those having the same 
region from the low-abundance spacer. Finally, due to the impossibility of testing 
every acquired spacer via oligo transformation, I evaluated the importance of this 
sequence within the entire set of acquired spacers. To do this, I used kpLogo94 to 
look for a conserved motif in the PAM-proximal 10-nt sequence of either the most 
abundant spacers (in the top 1 %, of average spacer reads in Fig. 1c). This 
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analysis yielded two motifs, corresponding to the enriched and depleted 
consensus within this sequence (Figure 4-11d). I appended these motifs to the 
low abundance (“red”) spacer to check for their influence in spacer acquisition. I 
found that the PAM-proximal motif derived from highly abundant spacers 
dramatically increased spacer acquisition (Figure 4-10c). The overall results of 
these experiments demonstrate that specific DNA sequences located 
immediately upstream of the PAM have important effects on the frequency of 
acquisition of the 30-nt spacer determined by that PAM. 
4.4. Discussion 
Early studies of the type II CRISPR-Cas response to phage infection have 
shown that the population of surviving bacteria has a diverse content of new 
spacer sequences, some much more abundant than others40,90,91. In principle, 
the abundance of a spacer should be determined by two factors: its frequency of 
integration into the CRISPR array and its targeting capabilities95. Here I found 
that the abundance of most spacers is determined early during infection, when 
positive or negative selection for good or bad targeting, respectively, is still not a 
factor at play. In addition, there is a strong correlation between the abundance of 
most spacers acquired during infection with live phage and their abundance after 
transformation with sheared phage DNA, again, when targeting is not required for 
survival. Finally, I showed that the frequency of most spacers in the surviving 
population correlates directly with their frequency of acquisition. 
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The data presented here show that the spacer abundance that emerges 
after the type II CRISPR-Cas immune response is basically determined shortly 
after infection, depending mostly on the acquisition rate of each acquired 
sequence and not on its properties as a guide for Cas9 DNA cleavage. This is 
also the prediction of theoretical analysis95. Modeling of the CRISPR-Cas 
immune response determined that high spacer acquisition probabilities will lead 
to greater diversity in the spacer distribution, while strong selection of spacers 
providing better phage clearance will tend to homogenize the population of 
spacers in favor of the most effective one (“winner takes all” situation). Previous 
studies in our lab that evaluated the effect of the concentration of CRISPR-
adapted cells on immunity91,96 could provide an explanation for such model for 
the impact of spacer acquisition on their distribution. The results showed that at 
very low concentrations of immune cells there is a marked effect on the recovery 
of these immune cells after infection. In this situation, equivalent to low 
acquisition rates, leads to the positive selection of spacers that are better at 
targeting due to their position in the CRISPR array96 or because they guide Cas9 
to the phage genome immediately after its injection91. On the other hand, when 
CRISPR-immune cells have high concentrations, the targeting efficiency of the 
spacers does not impact the host’s growth after phage addition. Although both of 
these studies investigated single-spacer cultures, I believe that a similar scenario 
can happen during the infection of naïve cultures that acquired multiple 
(thousands) of new spacers. The high rate of acquisition of certain sequences 
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most of the immunity to the population, and no further selection of these 
sequences due to their targeting efficiency will take place. 
Our findings showed that spacer abundance is mostly determined at the 
acquisition stage of type II CRISPR-Cas immunity. The uneven distribution of 
different spacer sequences could be in principle explained by the existence of 
phage genomic regions that are better substrates for spacer acquisition. Indeed, 
this is the case for the regions that first enter the host cell91 and is a possible 
explanation for the clustering of highly abundant spacers from the 5’ end of the 
would effectively create a high concentration of immune cells that will provide 
ϕNM4γ4 genome (Figure 4-2a-b). However, even within this region (and also 
close to the cos site in ϕ12γ391) there is a wide spectrum of spacer 
abundance. Here I showed that one explanation for these different abundances 
is the intrinsic frequency of acquisition of a given spacer sequence. 
Mutagenesis analysis revealed that the 10-nt sequence at the PAM end of a 
spacer is determinant for its frequency of acquisition and that there are 
conserved nucleotides within this region critical for the acquisition process. The 
molecular mechanisms behind this preferential acquisition are intriguing. The 
current model of spacer acquisition by type II CRISPR-Cas systems involves 
three steps: phage DNA is degraded by AddAB to create the spacer 
substrates91,97, these are selected and processed by a Cas9-Cas1-Cas2-Csn2 
complex84 and finally the processed spacer sequence is integrated by the 
Cas1-Cas2 integrase into the CRISPR array98. Future experiments will 
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investigate the impact of specific spacer sequences in the efficiency of these 
steps. In summary, our study begins to uncover the rules that govern the 
generation of immunological diversity during the type II CRISPR-Cas response to 
phage infection, revealing that spacer acquisition, a unique feature of these 




CRISPR-Cas is a DNA-encoded, sequence-specific immune system that 
protects bacteria and archaea against phages and other genetic elements. The 
adaptive feature of CRISPR-Cas immune systems relies on their ability to 
memorize DNA sequences from invading molecules (acquisition) and allows 
them to rapidly adapt against new threats. While recent research has drastically 
improved our understanding of adaptation, future studies will continue to address 
outstanding questions about the molecular mechanisms and technological 
applications of CRISPR, in general, and spacer acquisition, in particular. 
Molecularly, the functions of Cas1 and Cas2, two signature proteins 
present in all CIRSPR systems, have been thoroughly investigated. In the type I 
CRISPR system of E. coli, the Cas1-Cas2 complex is bound to a partially 
duplexed dsDNA (pre-spacer)79. The complex recognizes specific sequences 
upstream the CRISPR array to ensure leader-polarized spacer integration. This 
process is facilitated by host factors such as IHF (integration host factor)99,100. 
Similar findings were reported in type II-A CRISPR system of Streptococcus 
pyogenes96,101,102.  Integration of the spacer into the arrays is mediated by the 
integrase activity of Cas179 and the presence of a correct PAM in the pre-spacer 
facilitates integration in the right orientation103.  
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By contrast, little is known about the other Cas proteins involved in spacer 
acquisition. In type I-C of Bacillus halodurans, Cas4 has been shown to enhance 
the formation of functional memory by assisting PAM-compatible spacer 
selection104. In type II, Csn2 and Cas9 form a complex with Cas1 and Cas284 and 
are involved in adaptation5. Structural studies have revealed that Csn2 forms a 
ring-like structure around DNA, suggesting that it might recruit other proteins 
involved in spacer selection or integration63. In addition, the tracrRNA is also 
required84, suggesting that the apo-Cas9 structure77, very different from holo-
Cas971, does not have the correct conformation to participate in spacer 
acquisition. In addition to destroying the invading virus, Cas9 specifies PAM-
flanking viral sequences during adaptation to ensure only functional spacers are 
acquired. This is in contrast to type I, where the Cas1-Cas2 complex is 
necessary and sufficient to direct incorporation of new spacers with correct 
PAMs. Therefore, the motif is sensed by only one protein in type II (Cas9)89, but 
by different protein complexes in type I: Cas1-Cas2 during acquisition and the 
Cascade complex during interference105. Recognition of the PAM by the Cascade 
leads to accelerated integration of new spacers with correct PAMs during primed 
acquisition. By contrast, priming is yet to be shown to be a feature of type II 
CRISPR systems. Future work will address these and other mechanistical and 
molecular aspects of spacer acquisition in different CRISPR-Cas systems. 
In recent studies89,106, the E. coli type I-E CRISPR-Cas adaptation 
machinery has been repurposed as a recording device to store information (such 
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as environmental signals) in the form of spacers in the CRISPR array. Because 
the adaptation frequency is relatively low, decoding requires deep sequencing of 
a population of cells. This limits the number of stimuli that can be recorded. Using 
hyperactive adaptation machinery such as hCas9 can boost the adaptation 
frequency and thus the recording capacity of such synthetic devices. Moreover, 
combined with introduction of sheared genomic DNA, the hyperactive CRISPR 
adaptation machinery is able to sample much larger genomes than the type I-E 
Cas1-Cas2 complex and can be used to generate diverse and unbiased gRNA 
libraries in vivo. Further optimization of CRISPR-based molecular recording 
technologies, such as TRACE106, will enable high throughput parallel temporal 
recordings of biological states, such as fluctuations in gene expression or 
metabolite concentration. 
Besides these direct applications of spacer acquisition, CRISPR has 
emerged as a powerful DNA-editing technology used across all fields of 
biomedical research. Furthermore, CRISPR is expected to have tremendous 
contributions to agriculture and treatment of human diseases. In the U.S., the first 
clinical trials of CRISPR to treat genetic disorders like beta-thalassemia and 
sickle cell disease are expected to begin in 2018. 
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Chapter VI. 
Material and Methods 
Bacterial strains and growth condit ions 
Cultivation of Staphylococcus aureus RN422072 was carried out in heart infusion 
broth (BHI) at 37°C. Whenever applicable, media were supplemented with 
chloramphenicol at 10 μg/mL, erythromycin at 10 μg/mL or spectinomycin at 
250 μg/mL to ensure maintenance of pC194, pE194 and pLZ12 derived 
plasmids, respectively, or 5 mM CaCl2 for phage adsorption. 
Directed evolution of cas9  
The cas9 gene was mutagenized at a low rate of 0-4.5 mutations/kb by error 
prone PCR using GeneMorph II Random Mutagenesis Kit. The mutant cas9 
amplicons were cloned into a backbone plasmid containing a spacer matching a 
TAG-adjacent target on ϕNM4γ4. The library was subjected to soft-agar lytic 
phage infection and surviving colonies were re-streaked on fresh plates. The 
TAG-cleaving efficiency of surviving colonies was individually assessed by phage 
propagation assays. 
Spacer acquisit ion assay 
Spacer acquisition assays of cells harboring the full CRISPR system of 
Streptococcus pyogenes were performed as described previously, both in liquid 
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and on plate84. For plate acquisition assays, overnight cultures were launched 
from single colonies and diluted to equal optical densities. CRISPR arrays were 
amplified by PCR with primer pairs L400-H050 or L400-H052 (Supplementary 
table S3). 
Bacterial growth curves 
Overnight cultures were launched from single colonies and diluted 1:100 in BHI. 
After 1 hour of growth, optical density at 600 nm (OD600) was measured for each 
culture, and samples were brought to equal cell densities and loaded into 96-well 
plates along with ϕNM4γ4 at MOI =1. Measurements were taken every 10 
minutes for 24 hours. 
Cas9 target cleavage assay 
Cas9 was expressed and purified as previously described (Jinek et al., 2012). 
The I473F Cas9 expression vector was cloned by around-the-horn mutagenic 
PCR. crRNA and tracrRNA were transcribed using T7 RNA polymerase from 
single-stranded DNA templates and hybridized as previously described34,67. L2 
oligonucleotides (Supplementary table S3) were hybridized to generate the two 
different target DNA duplexes and native PAGE-purified before 5’ radiolabeling 
using [γ-32P]-ATP (Perkin-Elmer) and T4 polynucleotide kinase (New England
Biosciences). Cleavage assays were carried out essentially as previously 
described (Sternberg et al., 2014). In brief, Cas9 and crRNA:tracrRNA were 
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allowed to form an RNP complex before addition of target DNA. Final 
concentration of RNP was 100 nM and target was 1 nM. Reactions were 
incubated at room temperature, and aliquots were taken at 0.25, 0.5, 1, 2, 5, 10, 
30, and 60 minutes and quenched by addition of an equal volume of 95% 
formamide and 50 mM EDTA. Samples were run on 10% urea-PAGE, visualized 
by phosphorimaging, and quantified using ImageQuant (GE Healthcare). 
cleavage by Cas9 of various targets was assessed using the Guide-It Complete 
sgRNA Sreening System from Clontech (Cat. No. 632636) with minor 
modifications. Cas9 and the sgRNAs were pre-incubated for 5 min at 37C in 
equimolar ratio and then diluted into the cleavage reaction to final concentrations 
of 100, 50, 25, 12.5 and 6.25nM. All reactions contained 10nM of a phage-
derived PCR template with the target site. All reactions were stopped after 
5 minutes by heat inactivation at 80C for 5 minutes and stored at -80C until ready 
to be run on an agarose gel. 
Phage Interference Assay 
Overnight cultures were launched from single colonies. Serial dilutions of a stock 
of phage φNM4γ464 were spotted on fresh soft heart infusion agar (HIA) lawns of 
targeting cells containing chloramphenicol 10 μg/ml and 5 mM CaCl2. Plates 
were incubated at 37 °C overnight and interference efficiency was measured in 
plaque forming units (pfu). 
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Acquisit ion from live phage 
Acquisition from live phage in cells harboring the CRISPR system of 
Streptococcus pyogenes (plasmid pWJ40) or CRISPR3 of Streptococcus 
thermophilus (pRH200) was performed as described previously84. In Figure 4-3 
and 4-4, plasmid pWJ40* containing randomized leader barcodes was used 
instead of pWJ4092. The unweighted probability Logo of the top 1% protospacers 
was generated using kpLogo94. 
Acquisit ion from shredded phage DNA  
Phage DNA was shredded by sonication to fragments of ~150bp as described91. 
Following dialysis, 100μg of phage DNA was electroporated into competent S. 
aureus cells carrying plasmids pRH317 and pRH318*. Cells were recovered for 
2h in BHI supplemented with anhydrotetracycline at 1μg/μl. 
Acquisit ion from dsDNA oligos 
dsDNA substrates were obtained by annealing ssDNA oligos in Duplex Buffer 
from IDT. Following dialysis, 100nm of each competing dsDNA substrate were 
mixed and electroporated in competent S. aureus cells carrying plasmids 
pRH223 and pRH24084. Cells were recovered for 2h in BHI supplemented with 
anhydrotetracycline at 1μg/μl. Need to write the electroporated oligos for all 
samples either here or in a table. 
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High-throughput sequencing 
Plasmid DNA was extracted from adapted cultures. 200 ng of plasmid DNA was 
used as template for Phusion PCR to amplify the CRISPR locus with primer pairs 
H370-H371 (Figure 4-1, 4-2d), H180-B153 (Figure 4-2e), H370-H366 (Figure 4-5, 
early timepoint), H372-H366 (Figure 4-5, late timepoint) and H186-H366 (oligo 
electroporation). Following gel extraction and purification of the adapted bands, 
samples were subject to Illumina MiSeq (Figures 4-1, 4-2, 4-5, 4-6, 4-7) or 
NextSeq (Figures 4-3, 4-4) sequencing. Data analysis was performed in Python: 
first, all newly acquired spacer sequences were extracted from raw MiSeq 
FASTA data files. Next, the frequency, number of different barcodes, the phage 
target location, and the flanking PAM were determined for each unique spacer 
sequence. Analysis was finished in Excel. 
On-plate spacer acquisit ion assay 
To detect individual adapted colonies on a plate, cells from overnight cultures 
were mixed with phage at a m.o.i. value of 1 in top agar containing appropriate 
antibiotic and 5 mM CaCl2. The mixture was poured on BHI plates with antibiotic 
and incubated at 37 °C overnight. Subsequently, colonies that survived phage 
infection were re-streaked on fresh BHI plates in order to remove contaminating 
virus and dead cells. Plates were incubated at 37 °C overnight. To check for 
spacer acquisition, individual colonies were resuspended in lysis buffer (250 mM 
KCl, 5 mM MgCl2 50 mM Tris-HCl at pH 9.0, 0.5% Triton X-100), treated with 50 
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ng μl−1 lysostaphin and incubated at 37 °C for 5 min, then 98 °C for 5 min. 
Following centrifugation (16,000g), a sample of the supernatant was used as 
template for TopTaq PCR amplification with primers L400 and H050. The PCR 
reactions were analyzed on 2% agarose gels (Fig. 2-1a). 
Spacer Acquisit ion Enrichment PCR 
Overnight cultures launched from single colonies were diluted 1:1,000 into a 
fresh 10-ml culture of BHI containing appropriate antibiotic and 5 mM CaCl2. 
When the cultures reached D600 nm of 0.4, depending on the experiment, they 
were either infected with phage MOI value of 1 (Fig. 2-1b) or induced with 1 μg 
ml−1 anhydrotetracycline (Fig. 2-1c). After 16 h, plasmids carrying the CRISPR 
systems were extracted using a slightly modified QIAprep Spin Miniprep Kit 
protocol: the pelleted bacterial cells were resuspended in 250 μl buffer P1 
containing 50 ng μl−1 lysostaphin and incubated at 37 °C for 1 h, followed by the 
standard QIAprep protocol. 100 ng of plasmid DNA was used to amplify the 
CRISPR locus using Phusion DNA Polymerase (New England Biolabs) with the 
following primer mix: 3 parts JW8 and 1 part each of JW3, JW4 and JW5 
(Extended Data Table 4). The following cycling conditions were used: (1) 98 °C 
for 30 s; (2) (for 30 times) 98 °C for 10 s, 64 °C for 20 s, 72 °C for 10 s; (3) 72 °C 
for 5 min. The PCR reactions were analyzed on 2% agarose gels. To sequence 
individual spacers, the adapted bands were extracted, gel-purified and cloned via 
Zero Blunt TOPO PCR Cloning Kit (Invitrogen). CRISPR loci of individual clones 
111	
were checked for expansion of the arrays by PCR using the primers listed above 
and sent for sequencing. 
Phage adsorption assay 
The phage adsorption assay was performed as described previously30 with 
minor modifications. Cells were grown in BHI and 10 mM CaCl2 to a D600 nm 
(OD600) of 0.4. The phage solution was prepared at 106 plaque-forming units 
(p.f.u.) per ml and 100 µl of this was added to 900 µl of cells. The mixture was 
incubated for 10 min at 37 °C to allow adsorption of the phage to the cellular 
membrane. The mixture was centrifuged for 1 min at 16,000g and the number of 
phage particles left in the supernatant was determined by phage titer assay. 
Plasmid construction 
Construction of pWJ40 was described elsewhere17. For the construction of 
pC194-derived and pE194-derived plasmids, cloning was performed using 
chemically competent S. aureus cells, as described previously17. The Δcas1 
(pRH059), Δcas2 (pRH061) and Δcsn2 (pRH063) mutants were constructed by 
one-piece Gibson assembly31 from pWJ40 using the pairs of primers H016–
H017, H018–H019, H020–H021, respectively (Extended Data Table 4). Plasmid 
pRH087 containing the wild type cas genes of S. pyogenes was obtained by 
inserting the first spacer of S. pyogenes (annealed primers H049 and H050 
containing compatible BsaI overhangs) in pDB184 using BsaI cloning32. BsaI 
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cloning was also used to construct pRH079 and pRH233 by inserting a ϕNM4γ4 
targeting spacer (annealed primers H029 and H030) into pDB114 and pDB184, 
respectively. Plasmid pRH200 harbours the wild-type CRISPR3 system from S. 
thermophilus LMD-9 amplified with H168 and H169 from genomic DNA. The 
fragment was inserted on pE194 via Gibson assembly using H166 and H167. 
pRH213 was constructed by replacing Cas9Sp on pRH087 with Cas9St from 
pRH200 using the primer pairs H232–H233 and H231–H234, respectively. 
pRH214 was constructed by replacing Cas9St on pRH200 with Cas9Sp from 
pRH087 using the primer pairs H227–H230 and H228–H229, respectively. 
pGG32 was created by reducing the CRISPR locus of pWJ40 to a single repeat. 
This was accomplished by ‘round the horn’ PCR33 using primers oGG82 and 
oGG83, followed by blunt ligation. pRH228 was constructed by replacing Cas9Sp 
on pGG32 with Cas9St from pRH200 using the primer pairs H232–H233 and 
H231–H234, respectively. pRH223 was constructed as a three-piece Gibson 
assembly combining TetR+ptet from pKL55-iTet (primers B534 and B616), 
pE194 (primers B532 and B617) and the cas1, cas2, csn2 genes and the array 
from pGG32 (primers H176–H177). pRH231 was constructed from pGG32 by 
one-piece Gibson assembly with primers H289–H290. pRH234 contains Cas1 
E220A and was constructed via one-piece Gibson assembly from pRH223, 
respectively, using the primer pair H312–H313. pRH227 was constructed from 
pGG32 via two sequential single-piece Gibson assemblies: first, D10A was 
introduced with B337–B338 and second, H840A was introduced with B339–
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B340. pRH229 was constructed via one-piece Gibson assembly from pGG32 
using the primer pair H276–H277. Plasmids pRH240, pRH241, pRH242, pRH243 
and pRH244 were constructed by one-piece Gibson assembly with primers 
H237–H238 from pGG32, pRH228, pRH227, pRH229 and pRH231, respectively. 
pRH245 was constructed from pRH241 via two sequential single-piece Gibson 
assemblies: first, D10A was introduced with H336–H337 and second, H847A 
was introduced with H338–H339. Plasmid pRH317 was constructed by deleting 
the CRISPR leader and array from pRH22384 via a one-piece Gibson assembly 
reaction with primer pair JM126-JM127. Plasmid pRH318 was constructed by a 
two-piece Gibson assembly reaction from pRH24084 and pLZ12 with primer pairs 
H558-H559 and H555-H557, respectively. Plasmid pRH318* (containing 
randomized leader barcodes) was constructed by a two-piece Gibson assembly 
with primers pairs H378-H294 and H379-H293. Plasmid pRH248, pRH249, 
pRH328 and pRH328 were constructed BsaI cloning as described in Heler 
Nature with annealed oligo pairs H433-H434, H435-H436, H641-H642, and 
H643-H645, respectively. 
Isolation and sequencing of ϕNM4γ4
For the initial isolation of ϕNM4, supernatants from overnight cultures of S. 
aureus Newman were filtered and used to infect soft agar lawns of TB4:: ϕNM1,2 
double lysogens. A single plaque was picked and then plaque-purified in two 
additional rounds of infection using TB4 soft agar lawns, and subsequently used 
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to lysogenize TB4. For the resultant lysogen, specific primers were used to verify 
the presence of ϕNM4 and the absence of ϕNM1,2 by colony PCR. High titer 
lysates of ϕNM4 (∼1011 p.f.u. per ml) were then prepared from this lineage and 
used for infection of TB4/pGG9 soft agar lawns harboring spacer 2B17. An 
escaper plaque was picked and then plaque-purified in two additional rounds of 
infection using TB4/pGG9 soft agar lawns. The resultant ϕNM4γ4 phage 
exhibited a clear plaque phenotype and was used to prepare a high titre lysate 
from which DNA was purified, deep sequenced, and assembled as described 
previously. The full sequence of the ϕNM4γ4 has been deposited in GenBank 
under accession number KP209285 and includes a 2,784 bp deletion 
encompassing the C-terminal 80% of the ϕNM4 cI-like repressor gene. 
Protein purif ication of Cas9 
pMJ806 (wild-type Cas9) plasmid was obtained from Addgene. The proteins 
were purified as described before6 with minor modifications as follows. The 
proteins were expressed in E. coli BL21 Rosetta 2(DE3) codon plus cells (EMD 
Millipore). Cultures (2 litres) were grown at 37 °C in Terrific Broth medium 
containing 50 μg ml−1 kanamycin and 34 μg ml−1 chloramphenicol until the 
D600nm reached 0.6. The cultures were supplemented with 0.2 mM isopropyl-1-
thio-β-D-galactopyranoside and incubation was continued for 16 h at 16 °C with 
constant shaking. The cells were collected by centrifugation and the pellets 
stored at −80 °C. All subsequent steps were performed at 4 °C. Thawed bacteria 
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were resuspended in 30 ml of buffer A (50 mM Tris–HCl pH 7.5, 500 mM NaCl, 
200 mM Li2SO4, 10% sucrose, 15 mM imidazole) supplemented with complete 
EDTA free protease inhibitor tablet (Roche). Triton X-100 and lysozyme were 
added to final concentrations of 0.1% and 0.1 mg ml−1, respectively. After 30 
min, the lysate was sonicated to reduce viscosity. Insoluble material was 
removed by centrifugation for 1 h at 16,200g in a Beckman JA-3050 rotor. The 
soluble extract was bound in batch to mixed for 1 h with 5 ml of Ni2+-
Nitrilotriacetic acid-agarose resin (Qiagen) that had been pre-equilibrated with 
buffer A. The resin was recovered by centrifugation, and then washed extensively 
with buffer A. The bound protein was eluted step-wise with aliquots of IMAC 
buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 10% glycerol) containing 
increasing concentrations of imidazole. The 200 mM imidazole elutes containing 
the His6-MBP tagged Cas9 polypeptide was pooled together. The His6-MBP 
affinity tag was removed by cleavage with TEV protease during overnight dialysis 
against 20 mM Tris-HCl pH 7.5, 150 mM KCl, 1 mM TCEP and 10% glycerol. The 
tagless Cas9 protein was separated from the fusion tag by using a 5 ml SP 
Sepharose HiTrap column (GE Life Sciences). The protein was further purified by 
size exclusion chromatography using a Superdex 200 10/300 GL in 20 mM Tris 
HCl pH 7.5, 150 mM KCl, 1 mM TCEP, and 5% glycerol. The elution peak from 
the size exclusion was aliquoted, frozen and kept at −80 °C. 
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Plasmid pKW01 (wild-type Cas1) was constructed by through amplification of 
pWJ40 as a template for polymerase chain reactions (PCRs) to clone Cas1 into 
pET28b-His10Smt3 using the primers PS192 and PS193 (Extended Data Table 
4). Full sequencing of cloned DNA fragment confirmed perfect matches to the 
original sequence. The pKW01 plasmid was transformed into E. coli BL21 (DE3) 
Rosetta 2 cells (EMD Millipore). Cultures were grown and protein was purified by 
Ni-affinity chromatography step, as mentioned before in Cas9 purification. The 
200 mM imidazole elutes containing the His10-Smt3 tagged Cas1 polypeptide 
was pooled together. The His10-Smt3 affinity tag was removed by cleavage with 
SUMO protease during overnight dialysis against 50 mM Tris-HCl pH 7.5, 250 
mM NaCl, 20 mM imidazole and 10% glycerol. The tagless Cas1 protein was 
separated from the fusion tag by using a second Ni-NTA affinity step. The protein 
was further purified by size exclusion chromatography using a Superdex 200 
10/300 GL in 20 mM Tris HCl pH 7.5, 500 mM KCl, 1 mM TCEP, and 5% 
glycerol. The elution peak from the size exclusion was aliquoted, frozen and kept 
at −80 °C. 
Protein purif ication of Cas2 
The sequence encoding Cas2 was PCR amplified with primers PS334 and 
PS335 from pWJ40 and inserted into a pET-His6 MBP TEV cloning vector 
(Addgene Plasmid number 29656) using ligation independent cloning (LIC). 
Sequencing of the resultant plasmid (pPS059) confirmed the matches to the wild-
Protein purif ication of Cas1 
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type sequence. The protein was expressed and purified following the same 
procedure as that for Cas9. 
Protein purif ication of Csn2 
Plasmid pPS060 was constructed by through amplification of pWJ40 as a 
template for polymerase chain reactions (PCRs) to clone Csn2 into pET28b-
His10Smt3 using the primers PS336 and PS337. Full sequencing of cloned DNA 
fragment confirmed perfect matches to the original sequence. Csn2 was 
expressed and purified following the same method as that of Cas1. Previously 
Csn2 was shown to form a tetramer34. Protein concentrations for all the 
purifications were determined by using the Bradford dye reagent with BSA as the 
standard. 
Protein purif ication of Cas9–Cas1–Cas2–Csn2 complex 
pKW07 (His10-Cas9–Cas1–Cas2–Csn2) was constructed by amplification of 
pWJ40 with primers PS199/PS202 and pET16b (Novagen) with primers 
PS200/PS203, followed by Gibson assembly of the fragments. Full sequencing of 
cloned DNA fragment was done to confirm perfect matches to the original 
sequence. The proteins were expressed in E. coli BL21 Rosetta 2(DE3) codon 
plus cells (EMD Millipore). Cultures were grown and protein was purified by Ni-
affinity chromatography step, as mentioned before in Cas9 purification with minor 
modifications. The 200 mM imidazole eluates were dialysed overnight against 20 
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mM Tris-HCl pH 7.5, 150 mM KCl, 1 mM TCEP and 10% glycerol and subjected 
to mass spectrometry for the identification of the co-purifying proteins. pKW06 
(Cas9–Cas1–Cas2–Csn2–His6) was constructed by amplification of pWJ40 with 
primers PS204/PS205 and pET23a (Novagen) with primers PS206/PS207 
(Extended Data Table 4), followed by Gibson assembly of the fragments. Full 
sequencing of cloned DNA fragment was done to confirm perfect matches to the 
original sequence. The proteins were expressed in E. coli BL21 Rosetta 2(DE3) 
codon plus cells (EMD Millipore). Cultures were grown and protein was purified 
by Ni-affinity chromatography step, as mentioned before in Cas9 purification with 
minor modifications. The 200 mM imidazole eluates were dialysed overnight 
against 20 mM Tris-HCl pH 7.5, 150 mM KCl, 1 mM TCEP and 10% glycerol. The 
proteins were further purified using a 5 ml SP Sepharose HiTrap column (GE Life 












































































H065 GAT ATA ATG GGA GAT AAG ACG GTT C 
































































































































































































































H278 ORDERED. CHECK SEQUENCE 




































































































































TTC AGT TTT GGG ACC ATT CAA AAC AGC ATA GCT CTA AAA CTT ACC T 
H401 
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